US20120122883A1 - New salts - Google Patents
New salts Download PDFInfo
- Publication number
- US20120122883A1 US20120122883A1 US13/131,926 US200913131926A US2012122883A1 US 20120122883 A1 US20120122883 A1 US 20120122883A1 US 200913131926 A US200913131926 A US 200913131926A US 2012122883 A1 US2012122883 A1 US 2012122883A1
- Authority
- US
- United States
- Prior art keywords
- crystalline
- benzimidazol
- piperazin
- dihydro
- trifluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000013078 crystal Substances 0.000 claims description 77
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 74
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 74
- 239000000843 powder Substances 0.000 claims description 62
- 238000002844 melting Methods 0.000 claims description 61
- 230000008018 melting Effects 0.000 claims description 61
- 150000001875 compounds Chemical class 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 29
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 26
- 208000002193 Pain Diseases 0.000 claims description 24
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 23
- 208000008589 Obesity Diseases 0.000 claims description 22
- 235000020824 obesity Nutrition 0.000 claims description 22
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 19
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims description 16
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 13
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims description 13
- 229960002053 flibanserin Drugs 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims description 10
- 238000002425 crystallisation Methods 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 10
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 8
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000012458 free base Substances 0.000 claims description 8
- 239000011541 reaction mixture Substances 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- 206010024419 Libido decreased Diseases 0.000 claims description 7
- 208000017020 hypoactive sexual desire disease Diseases 0.000 claims description 7
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 7
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 208000008811 Agoraphobia Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 206010034912 Phobia Diseases 0.000 claims description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 4
- 206010041250 Social phobia Diseases 0.000 claims description 4
- 208000027520 Somatoform disease Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000024732 dysthymic disease Diseases 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 210000004165 myocardium Anatomy 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 208000027753 pain disease Diseases 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 201000001716 specific phobia Diseases 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000010926 purge Methods 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 206010048627 thoracic outlet syndrome Diseases 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010002660 Anoxia Diseases 0.000 claims description 2
- 241000976983 Anoxia Species 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 206010004716 Binge eating Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 206010048962 Brain oedema Diseases 0.000 claims description 2
- 208000021465 Brief psychotic disease Diseases 0.000 claims description 2
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010065941 Central obesity Diseases 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 206010068631 Childhood depression Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000024254 Delusional disease Diseases 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 208000004483 Dyspareunia Diseases 0.000 claims description 2
- 206010013954 Dysphoria Diseases 0.000 claims description 2
- 206010017076 Fracture Diseases 0.000 claims description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 208000013016 Hypoglycemia Diseases 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- 206010027452 Metastases to bone Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000003430 Mitral Valve Prolapse Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000029549 Muscle injury Diseases 0.000 claims description 2
- 206010028923 Neonatal asphyxia Diseases 0.000 claims description 2
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims description 2
- 206010062501 Non-cardiac chest pain Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
- 208000007683 Pediatric Obesity Diseases 0.000 claims description 2
- 208000000450 Pelvic Pain Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims description 2
- 206010037779 Radiculopathy Diseases 0.000 claims description 2
- 206010067171 Regurgitation Diseases 0.000 claims description 2
- 208000020186 Schizophreniform disease Diseases 0.000 claims description 2
- 208000029899 Sexual aversion disease Diseases 0.000 claims description 2
- 208000019568 Shared Paranoid disease Diseases 0.000 claims description 2
- 208000028810 Shared psychotic disease Diseases 0.000 claims description 2
- 208000010040 Sprains and Strains Diseases 0.000 claims description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 2
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 2
- 208000026345 acute stress disease Diseases 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 230000007953 anoxia Effects 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000014679 binge eating disease Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 206010007776 catatonia Diseases 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 201000002342 diabetic polyneuropathy Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000018578 heart valve disease Diseases 0.000 claims description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
- 230000036543 hypotension Effects 0.000 claims description 2
- 230000002267 hypothalamic effect Effects 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 201000009941 intracranial hypertension Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 230000005906 menstruation Effects 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 210000004115 mitral valve Anatomy 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 230000004112 neuroprotection Effects 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
- 208000033300 perinatal asphyxia Diseases 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 208000022610 schizoaffective disease Diseases 0.000 claims description 2
- 208000012672 seasonal affective disease Diseases 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 230000036262 stenosis Effects 0.000 claims description 2
- 208000037804 stenosis Diseases 0.000 claims description 2
- 238000011477 surgical intervention Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000009897 systematic effect Effects 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 206010046947 vaginismus Diseases 0.000 claims description 2
- 230000001457 vasomotor Effects 0.000 claims description 2
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 229910001868 water Inorganic materials 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- 238000010586 diagram Methods 0.000 description 46
- 238000000634 powder X-ray diffraction Methods 0.000 description 36
- 238000002076 thermal analysis method Methods 0.000 description 33
- 239000013543 active substance Substances 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical group OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 15
- 239000012453 solvate Substances 0.000 description 14
- 229920002261 Corn starch Polymers 0.000 description 12
- 239000008120 corn starch Substances 0.000 description 12
- 150000004683 dihydrates Chemical group 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 7
- 150000004682 monohydrates Chemical group 0.000 description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 102220608300 Transcription factor SOX-2_H15Y_mutation Human genes 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 5
- 102220480686 Alkaline phosphatase, germ cell type_H17A_mutation Human genes 0.000 description 4
- 101100335626 Caenorhabditis elegans fum-1 gene Proteins 0.000 description 4
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 4
- 101100401100 Caenorhabditis elegans mes-1 gene Proteins 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- 102220479923 Leucine-rich repeat-containing protein 26_H11A_mutation Human genes 0.000 description 4
- 102220573775 Neuroendocrine protein 7B2_H18A_mutation Human genes 0.000 description 4
- 102220492046 Phospholipid scramblase 1_H12A_mutation Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102220614256 Transmembrane and coiled-coil domains protein 1_H14A_mutation Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 101150091051 cit-1 gene Proteins 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 4
- 239000001530 fumaric acid Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- -1 n-mthylpyrrolidone Chemical compound 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 125000005490 tosylate group Chemical group 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 3
- 101150092468 Slc13a1 gene Proteins 0.000 description 3
- 102220493341 Sodium/calcium exchanger 3_H34A_mutation Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 101150055766 cat gene Proteins 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 3
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 3
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101150031329 Ets1 gene Proteins 0.000 description 2
- 102220627349 Frataxin, mitochondrial_H45Y_mutation Human genes 0.000 description 2
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102100037204 Sal-like protein 1 Human genes 0.000 description 2
- 102220608717 Suppressor of cytokine signaling 2_H55D_mutation Human genes 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102220549936 Usher syndrome type-1C protein-binding protein 1_H41A_mutation Human genes 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- HJOVHMDZYOCNQW-UHFFFAOYSA-N isophorone Chemical compound CC1=CC(=O)CC(C)(C)C1 HJOVHMDZYOCNQW-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 101150116497 sacm1l gene Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 238000012982 x-ray structure analysis Methods 0.000 description 2
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102220479948 Alkaline phosphatase, germ cell type_H45A_mutation Human genes 0.000 description 1
- 102220629359 Annexin A10_C15A_mutation Human genes 0.000 description 1
- 102220629358 Annexin A10_C19A_mutation Human genes 0.000 description 1
- 102220629355 Annexin A10_C22A_mutation Human genes 0.000 description 1
- 102220629353 Annexin A10_C28A_mutation Human genes 0.000 description 1
- 102220628401 Annexin A10_C35A_mutation Human genes 0.000 description 1
- 102220628446 Annexin A10_C42A_mutation Human genes 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 1
- 101100347993 Caenorhabditis elegans nas-1 gene Proteins 0.000 description 1
- 101100083253 Caenorhabditis elegans pho-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102220555330 Caspase-4_H20A_mutation Human genes 0.000 description 1
- 102220546060 Cell surface hyaluronidase_F24A_mutation Human genes 0.000 description 1
- 102220546093 Cell surface hyaluronidase_H26A_mutation Human genes 0.000 description 1
- 102220546098 Cell surface hyaluronidase_H36A_mutation Human genes 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102220501459 Cytosolic iron-sulfur assembly component 3_H44A_mutation Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102220474002 Gamma-secretase subunit PEN-2_F25A_mutation Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102220511583 Kappa-casein_N10A_mutation Human genes 0.000 description 1
- 102220475870 Keratin, type I cytoskeletal 10_H13A_mutation Human genes 0.000 description 1
- 102220530095 Linker for activation of T-cells family member 2_F23A_mutation Human genes 0.000 description 1
- 102220626513 Mitochondrial intermediate peptidase_C32A_mutation Human genes 0.000 description 1
- 102220626875 Mitochondrial intermediate peptidase_C54A_mutation Human genes 0.000 description 1
- 102220481012 Myosin-binding protein H-like_H28A_mutation Human genes 0.000 description 1
- 102220641911 POC1 centriolar protein homolog A_C20A_mutation Human genes 0.000 description 1
- 102220641926 POC1 centriolar protein homolog A_H51A_mutation Human genes 0.000 description 1
- 102220492049 Phospholipid scramblase 1_H53A_mutation Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102220471760 Proteasome subunit alpha type-7_H27A_mutation Human genes 0.000 description 1
- 102220602851 Putative inactive neutral ceramidase B_H14C_mutation Human genes 0.000 description 1
- 102220520948 Putative neutrophil cytosol factor 1B_C44G_mutation Human genes 0.000 description 1
- 102220612258 Putative uncharacterized protein PIK3CD-AS1_H54D_mutation Human genes 0.000 description 1
- 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 102220493485 Sodium/calcium exchanger 3_N16A_mutation Human genes 0.000 description 1
- 102220468361 T cell receptor beta constant 1_H40A_mutation Human genes 0.000 description 1
- 102220580465 Thioredoxin domain-containing protein 11_N13A_mutation Human genes 0.000 description 1
- 102220472117 Transmembrane protein_H54A_mutation Human genes 0.000 description 1
- 102220482622 Tripartite motif-containing protein 73_C14A_mutation Human genes 0.000 description 1
- 102220482629 Tripartite motif-containing protein 73_C17A_mutation Human genes 0.000 description 1
- 102220482621 Tripartite motif-containing protein 73_C34A_mutation Human genes 0.000 description 1
- 102220482493 Tripartite motif-containing protein 73_C53A_mutation Human genes 0.000 description 1
- 102220482472 Tripartite motif-containing protein 73_C55A_mutation Human genes 0.000 description 1
- 101100115751 Trypanosoma brucei brucei dnaaf11 gene Proteins 0.000 description 1
- 102220549750 Ubiquitin D_H11D_mutation Human genes 0.000 description 1
- 102220540093 WD repeat and coiled-coil-containing protein_H12D_mutation Human genes 0.000 description 1
- 102220482694 Zinc finger protein 750_H43A_mutation Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102220362973 c.18C>A Human genes 0.000 description 1
- 102220370678 c.21C>A Human genes 0.000 description 1
- 102220414642 c.43C>A Human genes 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000010431 corundum Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical group CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000351 oxalooxy group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- DLRJIFUOBPOJNS-UHFFFAOYSA-N phenetole Chemical compound CCOC1=CC=CC=C1 DLRJIFUOBPOJNS-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 102220005610 rs1063739 Human genes 0.000 description 1
- 102200039386 rs115014558 Human genes 0.000 description 1
- 102200026945 rs121918101 Human genes 0.000 description 1
- 102200024044 rs1555523872 Human genes 0.000 description 1
- 102220074240 rs180177188 Human genes 0.000 description 1
- 102220045232 rs587781939 Human genes 0.000 description 1
- 102220264466 rs773865323 Human genes 0.000 description 1
- 102220058910 rs786201402 Human genes 0.000 description 1
- 102220093887 rs876659717 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- AQRYNYUOKMNDDV-UHFFFAOYSA-M silver behenate Chemical compound [Ag+].CCCCCCCCCCCCCCCCCCCCCC([O-])=O AQRYNYUOKMNDDV-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
- C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to crystalline salts of flibanserin, 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
- the aim of the invention is to provide new forms of flibanserin with advantageous properties for pharmaceutical use.
- examples of these parameters are the stability of effect of the starting substance under various environmental conditions, the stability during production of the pharmaceutical formulation and stability in the final compositions of the drug.
- the pharmaceutically active substance used to prepare the pharmaceutical compositions should therefore have great stability which is ensured even under different environmental conditions. This is absolutely essential to prevent pharmaceutical compositions being used which contain breakdown products, for example, in addition to the active substance itself. In such a case the content of active substance present in the pharmaceutical formulation might be lower than specified.
- the absorption of moisture reduces the content of pharmaceutically active substance as a result of the increased weight caused by the uptake of water.
- Pharmaceutical compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g. by the addition of suitable drying agents or by storing the drug in an environment where it is protected from moisture.
- the uptake of moisture may reduce the content of pharmaceutically active substance during manufacture if the pharmaceutical substance is exposed to the environment without being protected from moisture in any way.
- a pharmaceutically active substance should be, if at all, only slightly hygroscopic.
- the solubility of the active substance Another criterion which may be of exceptional importance under certain circumstances depending on the choice of formulation or the choice of manufacturing process is the solubility of the active substance. If for example pharmaceutical solutions are prepared (e.g. for infusions) it is essential that the active substance should be sufficiently soluble in physiologically acceptable solvents. It is also very important for drugs which are to be taken orally that the active substance should be sufficiently soluble.
- the problem of the present invention is to provide a pharmaceutically active substance which not only is characterised by high pharmacological potency but also satisfies the above-mentioned physicochemical requirements as far as possible.
- the aim of the present invention is to provide new crystalline salt forms of flibanserin, 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, which are characterized by advantageous physicochemical properties, especially improved solubility in water and minimized hygroscopicity
- Another embodiment of the present invention relates to the process for manufacture of new crystalline salt forms of 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one.
- Another embodiment of the present invention relates to pharmaceutical compositions containing the new crystalline salt forms of 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one and to their use as medicament.
- the present invention relates to the following salts and/or crystalline forms and/or crystalline salt forms of the compound 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one:
- the invention relates to a process for the preparation of the new crystalline salt forms of flibanserin as specified above under I) to XXIX).
- the free base of the compound of formula (I) is dissolved in a suitable solvent, such as TFE/water (80:20).
- a suitable solvent such as TFE/water (80:20) (depending on the acid).
- the free base of the compound of formula (I) is then mixed with the acid at a predetermined base/acid molar ratio, which is selected from 1:1 or 2:1 depending on the acid.
- the solvent is evaporated under reduced pressure.
- a suitable crystallization solvent is added to the reaction mixture, and the reaction mixture is slowly heated up to 50° C. (e.g. a heating rate of about 5° C./min).
- suitable solvents for the crystallization are ethanol, tetrahydrofuran, dichloromethane, n-mthylpyrrolidone, propyl acetate, methyl tert-butyl ether, 1,4 dioxane, 1,2-dimetoxyethane, water, 2,2,2, -trifloroethanol, chloroform, methanol, nitrobenzene, nitromethane, cyclohexanone, propionitrile, ethyl phenyl ether, diisobutyl keton, isophorone, water/ethanol (20/80), water/n-methylpyrrolidone (80/20), water/2,2,2-trifluoroethanol (20/80), water/acteone (20/80) and water/DMSO (80/20).
- the reaction mixture After staying for about 30 minutes at 50° C., the reaction mixture is slowly cooled down (e.g. at a cooling rate of 5° C./h) to a suitable crystallization temperature, which is for example between 20° C. or 3° C. The reaction mixture stays at this temperature until enough crystals are formed, which can then be collected, for example by filtration.
- a suitable crystallization temperature which is for example between 20° C. or 3° C.
- Tables 2.1 to 2.18 contain the single crystal data obtained in the analysis.
- the values of the X-ray powder reflections and intensities (normalized) as recorded for the crystalline salt forms in accordance with the present invention are displayed in the preceding tables 1.1 to 1.23.
- the values (d [ ⁇ ]) of the reflection peaks with the highest relative intensities the highest values of din the corresponding table characterizes this crystalline salt form.
- the value “2-theta [°]” denotes the angle of diffraction in degrees and the value “d [ ⁇ ] spacing” denotes the specified distances in ⁇ between the lattice planes.
- Fw formula weight
- T Temperature of data collection
- ⁇ wavelength of X-ray source
- D m calculated density
- ⁇ range Theta range of data collection
- a further object of the present invention is the use of the above salts and crystalline salt forms for the manufacture of a medicament for the treatment or prevention of the following diseases.
- the indication of the above salts and crystalline salt forms of the present invention may include all known indications for flibanserin, e.g. in the treatment of patients suffering from central nervous system disorders, in particular in affective disorders (e.g. depression like major depressive disorder, childhood depression, dysthymia, seasonal affective disorder, dysthymic disorder and minor depressive disorder; bipolar disorders), anxiety (incl. panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobia (simple phobia), social phobia (social anxiety disorder), obsessive-compulsive disorder (OCD), post-traumatic stress disorder, acute stress disorder, generalized anxiety disorder and anxiety disorder not otherwise specified), sleep and sexual disorders (e.g.
- affective disorders e.g. depression like major depressive disorder, childhood depression, dysthymia, seasonal affective disorder, dysthymic disorder and minor depressive disorder; bipolar disorders
- anxiety incl. panic disorder with or without agoraphobia, agoraphobia without history of panic
- hypoactive sexual Desire Disorder premenstrual disorders like premenstrual dysphoria, premenstrual syndrome, premenstrual dysphoric disorder; sexual aversion disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorders like dyspareunia, vaginismus, noncoital sexual pain disorder; sexual dysfunction due to a general medical condition and substance-induced sexual dysfunction), psychosis, schizophrenia (including the disorganized type, the catatonic type, the paranoid type, the undifferentiated type, the residual type of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, and psychotic disorder not otherwise specified), personality disorders, mental organic disorders, mental disorders in childhood, aggressiveness, age associated memory impairment, for neuroprotection, the treatment and/or prevention of neurodegenerative diseases as well as cerebral ischaemia of various origins (e.g.
- hypoglycaemia hypoxia
- anoxia brain trauma
- brain oedema amyotropic lateral sclerosis
- Huntington's disease Alzheimer's disease, hypotension, cardiac infarct, brain pressure (elevated intracranial pressure), ischaemic and haemorrhagic stroke (stroke), global cerebral ischaemia during stoppage of the heart, diabetic polyneuropathy, tinnitus, perinatal asphyxia, cardiac hypertrophia (thickening of the heart muscle) and cardiac insufficiency (weakness of the heart muscle); anorexia nervosa (incl.
- ADHD Attention Deficit Hyperactivity Disorder
- obesity incl. exogenic obesity, hyperinsulinaemic obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity and central obesity), urinary incontinence (incl.
- overactive bladder syndrome urgency, urge urinary incontinence, stress urinary incontinence, mixed urinary incontinence
- chronic pain incl. neuropathic pain, diabetic neuropathy, post-herpetic neuralgia (PHN), carpal tunnel syndrome (CTS), HIV neuropathy, phantom limb pain, complex regional pain syndrome (CPRS), trigeminal neuralgia/trigeminus neuralgia/tic douloureux, surgical intervention (e.g.
- diabetic vasculopathy capillary resistance or diabetic symptoms associated with insulitis, pain associated with angina, pain associated with menstruation, pain associated with cancer, dental pain, headache, migraine, trigeminal neuralgia, temporomandibular joint syndrome, myofascial pain muscular injury, fibromyalgia syndrome, bone and joint pain (osteoarthritis), rheumatoid arthritis, rheumatoid arthritis and edema resulting from trauma associated with burns, sprains or fracture bone pain due to osteoarthritis, osteoporosis, bone metastases or unknown reasons, gout, fibrositis, myofascial pain, thoracic outlet syndromes, upper back pain or lower back pain (wherein the back pain results from systematic, regional, or primary spine disease (radiculopathy), pelvic pain, cardiac chest pain, non-cardiac chest pain, spinal cord injury (SCI)-associated pain, central post-stroke pain, cancer
- salts and crystalline salt forms can be used for the treatment of disorders of sexual desire, more preferably for HSDD (Hypoactive Sexual Desire Disorder).
- HSDD Hydrophilic Sexual Desire Disorder
- the present invention also relates to pharmaceutical compositions comprising the above-mentioned salts or crystalline salt forms of the present invention.
- compositions may, for example, be presented in a form suitable for oral, rectal, parenteral administration or for nasal inhalation: preferred forms includes for example, capsules, tablets, coated tablets, ampoules, suppositories and nasal spray.
- the active ingredient may be incorporated in excipients or carriers con-ventionally used in pharmaceutical compositions such as, for example, talc, arabic gum, lactose, gelatine, magnesium stearate, corn starch, acqueous or non acqueous vehicles, polyvynil pyrrolidone, semisynthetic glicerides of fatty acids, benzalconium chloride, sodium phosphate, EDTA, polysorbate 80.
- the compositions are advantageously formulated in dosage units, each dosage unit being adapted to supply a single dose of the active ingredient.
- the dosis range applicable per day is between 0.1 to 400, preferably between 1.0 to 300, more preferably between 2 to 200 mg.
- Each dosage unit may conveniently contain from 0.01 mg to 100 mg, preferably from 0.1 to 50 mg.
- Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
- excipients for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
- excipients for example inert dilu
- Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
- the core may also consist of a number of layers.
- the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
- Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. of a flavouring such as vanilline or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
- a sweetener such as saccharine, cyclamate, glycerol or sugar
- a flavour enhancer e.g. of a flavouring such as vanilline or orange extract.
- suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
- Solutions for injection are prepared in the usual way, e.g. of with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, and transferred into injection vials or ampoules.
- preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid
- Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
- Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
- the harvested crystals may be characterized by X-ray powder diffraction and thermal analysis (DSC). If suitable single crystals grow, single crystal X-ray structure analysis may be performed. The following equipment was used to characterize the crystalline salts forms.
- XRPD patterns were obtained using a high throughput XRPD set-up.
- the plates were mounted on a Bruker GADDS diffractometer equipped with a Hi-Star area detector.
- the diffractometer was calibrated using Silver Behenate for the long d-spacings and corundum for the short d-spacings.
- the data collection was carried out at room temperature using monochromatic CuK ⁇ radiation in the region of 2 ⁇ between 1.5 and 41.5°.
- the diffraction pattern of each well was collected with an exposure time of 3-4 minutes.
- Suitable single crystals were selected and glued to a glass fibre, which is mounted on a X-ray diffraction goniometer.
- X-ray diffraction data were collected for the mounted crystals at a temperature of 233K using a KappaCCD system and MoK ⁇ radiation generated by a FR590 X-ray generator (Bruker Nonius Delft, The Netherlands).
- Unit-cell parameters and crystal structure were determined and refined using the software package maXus (Mackay et al., 1997).
- IGAsorp water sorption monitor from Hiden Isochema was used for the analysis of the hygroscopical behaviour at room temperature.
- Solubility of the different crystalline salt forms in water was determined by adding approx. 5 mg of compound into 5 ml of water at room temperature. The mixture was vigorously shaken for 2 hours at room temperature. Afterwards the undissolved solid was removed by filtering through a 0.45 ⁇ m PTFE filter, in the filtrate the dissolved amount of compound was determined by UV-spectroscopy.
- the process is illustrated by the following example of manufacturing process of the salts and crystalline salt forms, as can be done in parallel in 96 well assay plates (maximum volume of each well is about 200 ⁇ l).
- the finely ground active substance, lactose and some of the corn starch are mixed together.
- the mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried.
- the granules, the remaining corn starch and the magnesium stearate are screened and mixed together.
- the mixture is compressed to produce tablets of suitable shape and size.
- the finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened.
- the sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
- the active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water.
- the moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45° C. and the granules are then passed through the same screen.
- convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine.
- the tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc.
- the finished coated tablets are polished with wax.
- the substance and corn starch are mixed and moistened with water.
- the moist mass is screened and dried.
- the dry granules are screened and mixed with magnesium stearate.
- the finished mixture is packed into size 1 hard gelatine capsules.
- the active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic.
- the solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.
- the hard fat is melted. At 40° C. the ground active substance is homogeneously dispersed. It is cooled to 38° C. and poured into slightly chilled suppository moulds.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
Abstract
The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
Description
- The present invention relates to crystalline salts of flibanserin, 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
- The compound 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one is known from
EP 0 526 434 B1 and has the following chemical structure, depicted below as Formula (I) - Furthermore, the free base of this compound is known from EP 1 414 816 B1 in its polymorph B form, as well as a process for its manufacture.
- The above mentioned patents further disclose the use of this compound for the treatment of different diseases inter alia for the treatment of HSDD (Hypoactive Sexual Desire Disorder).
- The aim of the invention is to provide new forms of flibanserin with advantageous properties for pharmaceutical use.
- The above mentioned pharmacologically valuable properties of flibanserin disclosed in the prior art constitutes the basic prerequisite for effective use of the compound as pharmaceutical compositions. However, to be permitted for use as a medicament, an active substance must also satisfy further requirements, besides actually being effective for the desired indication. These parameters are largely to do with the physicochemical nature of the active substance.
- Without being restrictive, examples of these parameters are the stability of effect of the starting substance under various environmental conditions, the stability during production of the pharmaceutical formulation and stability in the final compositions of the drug. The pharmaceutically active substance used to prepare the pharmaceutical compositions should therefore have great stability which is ensured even under different environmental conditions. This is absolutely essential to prevent pharmaceutical compositions being used which contain breakdown products, for example, in addition to the active substance itself. In such a case the content of active substance present in the pharmaceutical formulation might be lower than specified.
- The absorption of moisture reduces the content of pharmaceutically active substance as a result of the increased weight caused by the uptake of water. Pharmaceutical compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g. by the addition of suitable drying agents or by storing the drug in an environment where it is protected from moisture. In addition, the uptake of moisture may reduce the content of pharmaceutically active substance during manufacture if the pharmaceutical substance is exposed to the environment without being protected from moisture in any way. Preferably, therefore, a pharmaceutically active substance should be, if at all, only slightly hygroscopic.
- Another criterion which may be of exceptional importance under certain circumstances depending on the choice of formulation or the choice of manufacturing process is the solubility of the active substance. If for example pharmaceutical solutions are prepared (e.g. for infusions) it is essential that the active substance should be sufficiently soluble in physiologically acceptable solvents. It is also very important for drugs which are to be taken orally that the active substance should be sufficiently soluble.
- The problem of the present invention is to provide a pharmaceutically active substance which not only is characterised by high pharmacological potency but also satisfies the above-mentioned physicochemical requirements as far as possible.
- Accordingly, the aim of the present invention is to provide new crystalline salt forms of flibanserin, 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, which are characterized by advantageous physicochemical properties, especially improved solubility in water and minimized hygroscopicity
- Another embodiment of the present invention relates to the process for manufacture of new crystalline salt forms of 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one.
- Another embodiment of the present invention relates to pharmaceutical compositions containing the new crystalline salt forms of 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one and to their use as medicament.
- In a first aspect, the present invention relates to the following salts and/or crystalline forms and/or crystalline salt forms of the compound 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one:
-
- I. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one chloride (form I) (=anhydrous form), characterized by a melting point of Tfus (onset)=215±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that two further weakly endothermic signals can be observed at approx. 122° C. and 186° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=15.99±0.05 Å, d=7.44±0.05 Å, d=3.98±0.05 Å and d=3.44±0.05 Å;
- II. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one chloride (form III) (=solvate form), characterized by a melting point of Tfus (onset)=217±5° C. which occurs during thermal analysis using DSC. The DSC is characterised in that two further weakly endothermic signals can be observed at approx. 56° C. and 121° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=16.43±0.05 Å, d=5.08±0.05 Å, d=4.35±0.05 Å, d=3.47±0.05 Å and d=7.66±0.05 Å;
- III. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one bromide (form I) (=solvate form), characterized by a melting point of Tfus (onset)=252±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that two further weakly endothermic signals can be observed at approx. 104° C. and 222° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=3.48±0.05 Å, d=3.33±0.05 Å, d=4.28±0.05 Å, d=3.43±0.05 Å and d=16.03±0.05 Å;
- IV. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one bromide (form III) (=solvate form), characterized by a melting point of Tfus (onset)=252±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that two further weakly endothermic signals can be observed at approx. 89° C. and 218° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=15.52±0.05 Å, d=5.15±0.05 Å, d=4.60±0.05 Å, d=4.36±0.05 Å and d=3.94±0.05 Å;
- V. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one edisylate (form I) (=solvate form), characterized by a melting point of Tfus (onset)=144±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=14.34±0.05 Å, d=3.95±0.05 Å, d=4.64±0.05 Å, d=3.75±0.05 Å and d=9.50±0.05 Å;
- VI. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one tosylate (form I) (hydrated form), characterized by a melting point of Tfus (onset)=238±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=5.11±0.05 Å, d=4.84±0.05 Å, d=3.93±0.05 Å and d=3.48±0.05 Å;
- VII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one mesylate (form I) (=monohydrate form, characterized by a melting point of Tfus (onset)=207±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that one further weakly endothermic signal can be observed at approx. 60° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=15.25±0.05 Å, d=4.18±0.05 Å, d=3.47±0.05 Å, d=4.95±0.05 Å and d=4.24±0.05 Å; Its solubility in water at room temperature is 1.1 mg/ml. The hygroscopiycity expressed in the uptake of water in the range of 10-90% relative humidity is 3.4%.
- VIII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one besylate (form I) (=monohydrate form), characterized by a melting point of Tfus (onset)=247±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that one further weakly endothermic signal can be observed at approx. 111° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=3.99±0.05 Å, d=4.69±0.05 Å, d=4.85±0.05 Å and d=6.42±0.05 Å; Its solubility in water at room temperature is 0.1 mg/ml. The hygroscopiycity expressed in the uptake of water in the range of 10-90% relative humidity is 0.15%.
- IX. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one oxalate (form I) (=anhydrous form), characterized by a melting point of Tfus (onset)=209±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=7.09±0.05 Å, d=6.01±0.05 Å, d=4.92±0.05 Å, d=4.24±0.05 Å and d=4.08±0.05 Å; Its solubility in water at room temperature is 1.7 mg/ml. The hygroscopiycity expressed in the uptake of water in the range of 10-90% relative humidity is 0.7%.
- X. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one oxalate (form V) (=dihydrate form), characterized by a melting point of Tfus (onset)=254±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that two further weakly endothermic signals can be observed at approx. 112° C. and 198° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=7.09±0.05 Å, d=5.67±0.05 Å, d=5.04±0.05 Å, d=4.87±0.05 Å and d=3.76±0.05 Å;
- XI. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one sacharinate (form I) (=1.5 hydrated form), characterized by a melting point of Tfus (onset)=90±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=7.86±0.05 Å, d=5.90±0.05 Å, d=5.30±0.05 Å, d=5.14±0.05 Å and d=4.62±0.05 Å; Its solubility in water at room temperature is 0.3 mg/ml. The hygroscopiycity expressed in the uptake of water in the range of 10-90% relative humidity is 0.24%.
- XII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one phosphate (form I) (=hemihydrate form), characterized by a melting point of Tfus (onset)=182±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that three further weakly endothermic signals can be observed at approx. 81° C., 141° C. and 164° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=15.79±0.05 Å, d=5.06±0.05 Å, d=7.90±0.05 Å and d=3.75±0.05 Å;
- XIII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one maleate (form I) (=THF solvate), characterized by a melting point of Tfus (onset)=98±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that a further weakly endothermic signal can be observed at approx. 78° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=9.58±0.05 Å, d=7.71±0.05 Å, d=6.13±0.05 Å, d=5.93±0.05 Å and d=4.62±0.05 Å;
- XIV. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one maleate (form III) (=anhydrous form), characterized by a melting point of Tfus (onset)=172±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=6.07±0.05 Å, d=5.16±0.05 Å, d=4.52±0.05 Å, d=4.10±0.05 Å and d=3.20±0.05 Å;
- XV. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one ethansulfonate (form I) (=monohydrate form), characterized by a melting point of Tfus (onset)=207±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that two further weakly endothermic signals can be observed at approx. 105° C. and 189° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=15.30±0.05 Å, d=7.25±0.05 Å, d=5.00±0.05 Å, d=4.34±0.05 Å and d=4.23±0.05 Å; Its solubility in water at room temperature is 1.3 mg/ml. The hygroscopiycity expressed in the uptake of water in the range of 10-90% relative humidity is 0.32%.
- XVI. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one camphorsulfonate (form I) (=anhydrous form), characterized by a melting point of Tfus (onset)=217±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that a further weakly endothermic signal can be observed at approx. 177° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=16.32±0.05 Å, d=5.69±0.05 Å, d=5.45±0.05 Å, d=5.50±0.05 Å and d=3.62±0.05 Å;
- XVII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one malonate (form I) (=dihydrate form), characterized by a melting point of Tfus (onset)=103±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that a further weakly endothermic signal can be observed at approx. 79° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=23.23±0.05 Å, d=8.56±0.05 Å, d=4.62±0.05 Å, d=4.19±0.05 Å and d=3.72±0.05 Å;
- XVIII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one malonate (form II) (=solvate form), characterized by the data listed in table 2.9;
- XIX. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one malonate (form VI) (=dihydrate form), characterized by the data listed in table 2.10;
- XX. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one salicylate (form I) (=anhydrous form), characterized by the data listed in table 2.11;
- XXI. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one L-tartrate (=dihydrate form), characterized by a melting point of Tfus (onset)=151±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=5.46±0.05 Å, d=4.94±0.05 Å, d=4.30±0.05 Å, d=4.08±0.05 Å and d=3.74±0.05 Å;
- XXII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one hemifumarate (form I) (=anhydrous form), characterized by a melting point of Tfus (onset)=195±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=6.38±0.05 Å, d=5.19±0.05 Å, d=4.87±0.05 Å, d=3.72±0.05 Å and d=3.45±0.05 Å;
- XXIII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one fumarate (form II) (=dihydrate form), characterized by a melting point of Tfus (onset)=193±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that a further weakly endothermic signal can be observed at approx. 157° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=5.42±0.05 Å, d=4.73±0.05 Å, d=4.25±0.05 Å, d=4.06±0.05 Å and d=3.72±0.05 Å;
- XXIV. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one glycolate (form I) (=hydrate form), characterized by a melting point of Tfus (onset)=139±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that two further weakly endothermic signals can be observed at approx. 30° C. and 115° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=3.96±0.05 Å, d=4.48±0.05 Å, d=3.93±0.05 Å, d=8.43±0.05 Å and d=3.74±0.05 Å;
- XXV. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one citrate (form I) (=solvate form), characterized by a melting point of Tfus (onset)=176±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that a further weakly endothermic signal can be observed at approx. 123° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=15.61±0.05 Å, d=7.81±0.05 Å, d=7.47±0.05 Å, d=5.34±0.05 Å and d=4.87±0.05 Å;
- XXVI. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one mandelate (form I) (=anhydrous form), characterized by a melting point of Tfus (onset)=148±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=4.87±0.05 Å, d=4.66±0.05 Å, d=4.10±0.05 Å, d=3.88±0.05 Å and d=3.73±0.05 Å;
- XXVII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one L-malate (form I) (=monohydrate form), characterized by a melting point of Tfus (onset)=176±5° C. which occurs during thermal analysis using DSC. The DSC diagram is additionally characterised in that a further weakly endothermic signal can be observed at approx. 106° C. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=7.82±0.05 Å, d=6.10±0.05 Å, d=5.22±0.05 Å, d=4.95±0.05 Å and d=3.79±0.05 Å;
- XXVIII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one succinate (form I) (=dihydrate form), characterized by the data listed in table 2.18;
- XXIX. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one naphthalenesulfonate (form I) (=hemihydrate form), characterized by peaks in the X-ray powder diffractogram which occur at d=4.92±0.05 Å, d=3.43±0.05 Å, d=4.00±0.05 Å and d=3.96±0.05 Å;
- XXX. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one tosylate (form II) (=anhydrous form), characterized by a melting point of Tfus (onset)=241±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=4.94±0.05 Å, d=4.57±0.05 Å, d=4.32±0.05 Å, d=3.53±0.05 Å and d=3.35±0.05 Å; Its solubility in water at room temperature is 0.09 mg/ml. The hygroscopiycity expressed in the uptake of water in the range of 10-90% relative humidity is 0.25%.
- XXXI. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one fumarate (form III) (=anhydrous form), characterized by a melting point of Tfus (onset)=202±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=5.33±0.05 Å, d=5.21±0.05 Å, d=4.53±0.05 Å, d=4.12±0.05 Å and d=3.69±0.05 Å; Its solubility in water at room temperature is 0.5 mg/ml. The hygroscopiycity expressed in the uptake of water in the range of 10-90% relative humidity is 0.28%.
- XXXII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one camphorsulfonate (form II) (=anhydrous form), characterized by a melting point of Tfus (onset)=231±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=5.47±0.05 Å, d=5.44±0.05 Å, d=4.76±0.05 Å, d=4.46±0.05 Å and d=3.70±0.05 Å; Its solubility in water at room temperature is 0.7 mg/ml. The hygroscopiycity expressed in the uptake of water in the range of 10-90% relative humidity is 0.13%.
- XXXIII. Crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one glycolate (form II) (=hydrate form), characterized by a melting point of Tfus (onset)=231±5° C. which occurs during thermal analysis using DSC. Particularly characteristic peaks in the X-ray powder diffractogram of this compound are d=5.75±0.05 Å, d=4.64±0.05 Å, d=4.43±0.05 Å, d=4.02±0.05 Å and d=3.97±0.05 Å; Its solubility in water at room temperature is 0.5 mg/ml. The hygroscopiycity expressed in the uptake of water in the range of 10-90 relative humidity is 0.20%.
- In another embodiment the invention relates to a process for the preparation of the new crystalline salt forms of flibanserin as specified above under I) to XXIX).
- According to the invention the compounds specified above can be obtained by
-
- i) dissolving the free base of flibanserin and the acid providing the anion for salt formation in a suitable solvent (preferably TFE/water (80:20))
- ii) mixing the free base of flibanserin with the acid at a predetermined base/acid molar ratio, which is selected from 1:1 or 2:1 depending on the acid
- iii) removing the solvent (e.g. evaporation under reduced pressure)
- iv) adding a suitable crystallization solvent to the residue obtained by step iii), and heating the reaction mixture slowly up (e.g. at a heating rate of about 5° C./min) to about 50° C.; leaving it to stand for a further period of time (e.g. about 30 min)
- v) slowly cooling down (e.g. at a cooling rate of about 5° C./h) the reaction mixture to a suitable crystallization temperature, (e.g. between 20° C. or 3° C.) and leaving it to stand until enough crystals are formed
- vi) isolating the precipitated crystals.
- In the process according to the invention the free base of the compound of formula (I) is dissolved in a suitable solvent, such as TFE/water (80:20). The acid used for the crystallization is dissolved as well in a suitable solvent, such as TFE/water (80:20) (depending on the acid). The free base of the compound of formula (I) is then mixed with the acid at a predetermined base/acid molar ratio, which is selected from 1:1 or 2:1 depending on the acid. Then, the solvent is evaporated under reduced pressure. After evaporation of the solvent has occurred, a suitable crystallization solvent is added to the reaction mixture, and the reaction mixture is slowly heated up to 50° C. (e.g. a heating rate of about 5° C./min). Without being limited, suitable solvents for the crystallization are ethanol, tetrahydrofuran, dichloromethane, n-mthylpyrrolidone, propyl acetate, methyl tert-butyl ether, 1,4 dioxane, 1,2-dimetoxyethane, water, 2,2,2, -trifloroethanol, chloroform, methanol, nitrobenzene, nitromethane, cyclohexanone, propionitrile, ethyl phenyl ether, diisobutyl keton, isophorone, water/ethanol (20/80), water/n-methylpyrrolidone (80/20), water/2,2,2-trifluoroethanol (20/80), water/acteone (20/80) and water/DMSO (80/20). After staying for about 30 minutes at 50° C., the reaction mixture is slowly cooled down (e.g. at a cooling rate of 5° C./h) to a suitable crystallization temperature, which is for example between 20° C. or 3° C. The reaction mixture stays at this temperature until enough crystals are formed, which can then be collected, for example by filtration.
- The salt forms of flibanserin as specified above under I) to XXIX) were investigated more thoroughly by X-ray powder diffraction and thermal analysis (DSC). The diagrams obtained are shown in
FIGS. 1.1 to 1.23. Tables 1.1 to 1.23 contain the data obtained in the analysis. - Tables 2.1 to 2.18 contain the single crystal data obtained in the analysis.
-
TABLE 1 Thermal analysis, stoichiometry and single crystal data of the different salts of 1-[2- (4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one single salt salt form ratio thermal analysis cyrstal XRPD form full name base/acid Tfus (onset) data data HCl 1 chloride, form I 1:1 T = 215° C. n.d. See (=anhydrous form) add. endotherm. signals: Table T = 122° C. (following by an 1.1a exotherm. signal) T = 186° C. (following by an exotherm. signal) HCl 3 chloride, form III 1:1 T = 217° C. n.d. See (=solvate form) add. endotherm. signals: Table T = 56° C. 1.1b T = 121° C. (following by an exotherm. signal) HBr 1 bromide from I 1:1 T = 252° C. n.d. See (=solvate form) add. endotherm. signals: Table T = 104° C. 1.2a T = 222° C. following by an exotherm. signal) HBr 3 bromide from III 1:1 T = 252° C. see See (=solvate form) add. endotherm. signals: Table Table T = 89° C. 2.1 1.2b T = 218° C. (following by an exotherm. signal) Eds 1 edisylate form I 1:1 T = 144° C. n.d. See (=solvate form) Table 1.3 Tos 1 tosylate form I 1:1 T = 238° C. n.d. See (hydrated form) Table 1.4 Mes 1 mesylate form I 1:1 T = 207° C. n.d. See (=monohydrate form) add. endotherm. signal: Table T1 = 60° C. 1.5 Bes 1 besylate form I 1:1 T = 247° C. n.d. See (=monohydrate form) add. endotherm. signal: Table T = 111° C. 1.6 Oxa 1 oxalate form I 1:1 T = 209° C. see See (=anhydrous form) Table Table 2.2 1.7a Oxa 5oxalate form V 1:1 T = 254° C. see See (=dihydrate form) add. endotherm. signal: Table Table T = 112° C. 2.3 1.7b T = 198° C. Sac1 sacharinate form I 1:1 T = 90° C. see See (1,5 hydrated form) Table Table 2.4 1.8 Pho phosphate form I 1:1 T = 182° C. n.d. See (=hemihydrate form) add. endotherm. signals Table T = 81° C. 1.9 T = 141° C. T = 164° C. Mae1 maleate form I 1:1 T = 98° C. see See (=THF solvate) add. endotherm. signal Table Table T = 78° C. 2.5 1.10a Mae3 maleate form III 1:1 T = 172° C. see See (=anhydrous form) Table Table 2.6 1.10b Ets ethanesulfonate 1:1 T = 207° C. see See (=monhydrate form) add. endotherm. signals: Table Table T = 105° C. 2.7 1.11 T = 189° C. (following by an exotherm. signal) Cas1 camphorsulfonate 1:1 T = 217° C. n.d. See form I add. endotherm. signal: Table (=anhydrous form) T = 177° C. 1.12 Mao 1 malonate form I 1:1 T = 103° C. see See (=dihydrate form) add. endotherm. signal: Table Table T = 79° C. 2.8 1.13 Mao 2 malonate form II 1:1 n.d. see n.d. (=solvate form) Table 2.9 Mao 6 malonate form VI 1:1 n.d. see n.d. (=dihydrate form) Table 2.10 Sal 1 salicylate form I 1:1 n.d. see n.d. (=anhydrous form) Table 2.11 L-Tart L-tartate form 1:1 T = 151° C. see See 1 (=dihydrate form) Table Table 2.12 1.14 Fum 1 fumarate form I 2:1 T = 195° C. see See (=anhydrous form) Table Table (co-crystal) 2.13 1.15a Fum 2 fumarate form II 2:1 T = 193° C. see See (=dihydrate form) add. endotherm. signal: Table Table T = 157° C. 2.14 1.15b Gly 1 glycolate form I 1:1 T = 139° C. n.d. See (=hydrate form) add. endotherm. signals: Table T = 30° C. 1.16 T = 115° C. (following by an exotherm. signal) Cit1 citrate form I 1:1 T = 176° C. see See (=solvate form) add. endotherm. signal: Table Table T = 123° C. 2.15 1.17 Man 1 mandelate form I 1:1 T = 148° C. see See (=anhydrous form) Table Table 2.16 1.18 L-Mal L-malate form I 1:1 T = 176° C. see See 1 (=monohydrate form) add. endotherm. signal: Table Table T = 106° C. 2.17 1.19 Suc 1 succinate form I 1:1 n.d. see n.d. (=dihydrate form) Table 2.18 Nas1 naphtalene- 1:1 n.d. n.d. See sulfonate form I Table (=hemihydrate form) 1.20 Tos 2 tosylate form II 1:1 T = 241° C. n.d. See (=anhydrous form) Table 1.21 Fum 3 fumarate, form III 1:1 T = 202° C. n.d. See (=anhydrous form) Table 1.22 Cas 2 camphorsulfonate 1:1 T = 231° C. n.d. See form II Table (=anhydrous form) 1.23 Gly 2 glycolate form II 1:1 T = 145° C. n.d. See (=hydrate form) Table 1.24 * Tfus (onset) = melting point; n.d. = not determined - The values of the X-ray powder reflections and intensities (normalized) as recorded for the crystalline salt forms in accordance with the present invention are displayed In the preceding tables 1.1 to 1.23. For each crystalline salt form, the values (d [Å]) of the reflection peaks with the highest relative intensities the highest values of din the corresponding table characterizes this crystalline salt form. The value “2-theta [°]” denotes the angle of diffraction in degrees and the value “d [Å] spacing” denotes the specified distances in Å between the lattice planes.
-
TABLE 1.1a X-ray powder reflections and intensity (normalized) of HCl1 = chloride, form I 2-theta d [Å] I/I0 [°] spacing [%] 5.18 17.05 32 5.52 15.99 100 6.23 14.20 8 7.01 12.59 10 8.75 10.10 38 9.18 9.62 13 9.50 9.30 11 10.36 8.53 15 10.94 8.08 11 11.06 7.99 11 11.88 7.44 63 13.41 6.59 38 13.93 6.35 17 14.18 6.24 18 14.97 5.91 22 15.18 5.83 17 15.49 5.71 16 16.22 5.46 28 16.94 5.23 25 17.14 5.17 32 17.55 5.05 34 18.33 4.83 21 19.64 4.52 27 20.22 4.39 17 21.00 4.23 48 21.38 4.15 22 22.32 3.98 62 22.64 3.92 21 23.00 3.86 16 23.52 3.78 19 24.51 3.63 11 25.85 3.44 54 26.30 3.38 33 27.04 3.29 41 27.66 3.22 13 27.78 3.21 17 28.11 3.17 24 28.31 3.15 23 28.80 3.10 13 29.23 3.05 19 29.48 3.02 16 30.13 2.96 17 -
TABLE 1.1b X-ray powder reflections and intensity (normalized) of HCl3 = chloride, form III 2-theta d [Å] I/I0 [°] spacing [%] 5.37 16.43 100 6.90 12.79 24 8.70 10.16 58 9.10 9.71 46 10.21 8.66 47 11.54 7.66 80 11.84 7.47 45 12.13 7.29 30 13.32 6.64 57 14.03 6.30 47 14.82 5.97 38 14.90 5.94 38 15.30 5.78 46 15.38 5.75 48 15.50 5.71 48 16.23 5.45 38 16.61 5.33 38 16.86 5.25 48 17.02 5.20 46 17.44 5.08 99 18.20 4.87 32 18.93 4.68 42 19.23 4.61 54 19.73 4.50 42 20.40 4.35 96 20.92 4.24 66 21.22 4.18 37 21.34 4.16 35 22.00 4.04 63 22.21 4.00 54 22.33 3.98 47 22.87 3.88 56 23.47 3.79 44 24.06 3.69 24 24.25 3.67 24 25.18 3.53 33 25.63 3.47 82 26.11 3.41 42 26.68 3.34 53 26.98 3.30 40 27.05 3.29 38 27.64 3.22 44 27.91 3.19 39 28.44 3.13 33 29.03 3.07 33 29.92 2.98 34 30.73 2.91 30 -
TABLE 1.2a X-ray powder reflections and intensity (normalized) of HBr1 = hydrobromide, form I 2-theta d [Å] I/I0 [°] spacing [%] 5.51 16.03 58 10.21 8.65 13 11.86 7.45 50 12.92 6.84 22 13.16 6.72 18 13.82 6.40 17 14.02 6.31 28 14.49 6.12 24 15.34 5.77 28 16.01 5.53 22 16.94 5.23 31 17.16 5.16 32 17.98 4.93 23 18.21 4.87 18 19.02 4.66 22 19.53 4.54 42 19.91 4.45 25 20.25 4.38 53 20.75 4.28 70 21.16 4.19 29 21.97 4.04 49 22.60 3.93 32 23.10 3.85 24 23.92 3.71 15 25.55 3.48 100 25.96 3.43 66 26.70 3.33 84 27.79 3.21 38 28.14 3.17 32 28.95 3.08 35 29.40 3.03 20 29.82 2.99 22 31.21 2.86 21 31.89 2.80 14 32.33 2.77 18 32.84 2.72 16 33.83 2.65 16 35.81 2.50 16 38.55 2.33 15 -
TABLE 1.2b X-ray powder reflections and intensity (normalized) of HBr3 = hydrobromide, form III 2-theta d [Å] I/I0 [°] spacing [%] 5.69 15.52 100 7.13 12.38 24 12.20 7.25 54 13.24 6.68 31 14.13 6.26 35 14.85 5.96 27 16.24 5.45 24 17.21 5.15 56 18.05 4.91 26 19.29 4.60 63 19.93 4.45 28 20.37 4.36 71 20.97 4.23 43 21.54 4.12 24 22.13 4.01 36 22.54 3.94 64 23.25 3.82 24 23.58 3.77 21 24.04 3.70 26 25.38 3.50 29 25.74 3.46 56 26.26 3.39 35 26.50 3.36 31 26.92 3.30 32 27.89 3.19 37 28.31 3.15 26 30.21 2.95 33 30.76 2.90 18 31.36 2.85 21 32.31 2.77 17 32.91 2.72 21 35.08 2.56 16 35.99 2.49 17 -
TABLE 1.3 X-ray powder reflections and intensity (normalized) of Eds1 = edisylate, form I 2-theta d [Å] I/I0 [°] spacing [%] 6.15 14.34 100 7.01 12.59 19 7.70 11.47 23 8.73 10.11 21 9.29 9.50 56 9.69 9.12 26 10.30 8.58 21 11.03 8.01 5 11.34 7.79 38 12.10 7.31 27 13.15 6.72 31 13.78 6.42 40 14.30 6.19 36 15.32 5.78 37 16.13 5.49 21 17.15 5.17 49 17.85 4.96 43 18.64 4.75 45 19.11 4.64 86 20.04 4.43 24 20.58 4.31 57 20.88 4.25 37 21.06 4.21 32 21.43 4.14 55 22.06 4.03 23 22.48 3.95 99 22.84 3.89 29 23.34 3.81 27 23.69 3.75 87 24.28 3.66 43 24.76 3.59 28 25.15 3.54 23 25.89 3.44 22 25.98 3.43 24 26.56 3.35 31 27.10 3.29 20 27.18 3.28 20 27.81 3.20 24 28.16 3.17 28 28.70 3.11 20 28.78 3.10 19 29.62 3.01 19 29.70 3.00 18 30.64 2.91 19 -
TABLE 1.4 X-ray powder reflections and intensity (normalized) of Tos1 = tosylate, form I 2-theta d [Å] I/I0 [°] spacing [%] 3.29 26.82 20 11.03 8.01 17 12.99 6.80 17 13.76 6.43 39 14.02 6.31 52 14.24 6.21 36 14.61 6.06 20 14.99 5.90 16 16.26 5.45 15 17.34 5.11 100 18.31 4.84 90 18.71 4.74 44 19.21 4.62 50 19.52 4.54 31 21.16 4.19 13 22.59 3.93 84 23.07 3.85 15 23.61 3.76 14 25.36 3.51 35 25.59 3.48 55 26.22 3.40 19 27.27 3.27 25 27.76 3.21 26 28.59 3.12 13 29.26 3.05 18 30.10 2.97 11 -
TABLE 1.5 X-ray powder reflections and intensity (normalized) of Mes1 = mesylate, form I 2-theta d [Å] I/I0 [°] spacing [%] 5.79 15.25 100 7.02 12.58 24 7.89 11.19 21 9.42 9.38 14 9.80 9.02 16 11.58 7.63 34 12.23 7.23 47 13.17 6.71 25 14.10 6.27 39 14.56 6.07 29 15.78 5.61 23 16.12 5.49 59 16.60 5.33 15 17.36 5.10 15 17.89 4.95 92 19.13 4.63 23 19.62 4.52 20 20.22 4.39 52 20.66 4.29 64 20.91 4.24 73 21.21 4.18 97 22.54 3.94 13 23.05 3.85 28 23.60 3.76 31 24.33 3.65 20 25.60 3.47 95 26.15 3.40 20 26.50 3.36 20 26.98 3.30 16 27.66 3.22 56 28.23 3.16 16 29.22 3.05 12 29.68 3.01 23 30.19 2.96 11 -
TABLE 1.6 X-ray powder reflections and intensity (normalized) of Bes1 = besylate, form I 2-theta d [Å] I/I0 [°] spacing [%] 3.45 25.61 33 8.71 10.14 9 9.65 9.16 9 11.23 7.87 10 11.70 7.56 11 12.42 7.12 10 13.77 6.42 60 14.28 6.19 45 15.28 5.79 14 15.89 5.57 11 17.42 5.08 55 18.27 4.85 62 18.90 4.69 72 19.77 4.48 15 20.49 4.33 41 21.77 4.08 12 22.26 3.99 100 22.54 3.94 33 22.90 3.88 32 23.91 3.72 15 24.18 3.68 18 24.63 3.61 14 24.97 3.56 11 25.58 3.48 54 26.06 3.41 32 26.94 3.31 28 27.25 3.27 21 27.64 3.22 15 27.99 3.18 11 28.35 3.14 16 28.95 3.08 11 29.96 2.98 14 30.76 2.90 10 -
TABLE 1.7a X-ray powder reflections and intensity (normalized) of Oxa 1, oxalate, form I 2-theta d [Å] I/I0 [°] spacing [%] 9.04 9.77 43 9.65 9.15 24 12.03 7.35 19 12.48 7.09 76 14.71 6.01 69 15.80 5.60 18 16.22 5.46 56 17.04 5.20 33 18.00 4.92 83 18.30 4.84 56 19.30 4.59 61 20.00 4.43 36 20.92 4.24 76 21.75 4.08 100 23.36 3.80 46 23.66 3.76 32 23.94 3.71 38 25.04 3.55 24 25.78 3.45 46 27.33 3.26 29 28.49 3.13 21 29.22 3.05 16 -
TABLE 1.7b X-ray powder reflections and intensity (normalized) of Oxa 5, oxalate, form V2-theta d [Å] I/I0 [°] spacing [%] 6.26 14.11 9 9.03 9.78 11 9.49 9.31 15 11.00 8.04 12 12.48 7.09 34 12.66 6.98 22 14.17 6.24 15 14.73 6.01 11 15.25 5.80 13 15.60 5.67 27 16.26 5.45 11 17.24 5.14 16 17.58 5.04 28 18.21 4.87 100 18.70 4.74 19 19.26 4.60 13 20.60 4.31 12 20.92 4.24 10 21.72 4.09 11 22.45 3.95 16 23.35 3.80 27 23.66 3.76 34 25.09 3.54 13 25.62 3.47 20 26.19 3.40 24 26.46 3.36 21 27.73 3.21 16 28.64 3.11 9 30.86 2.89 8 -
TABLE 1.8 X-ray powder reflections and intensity (normalized) of Sac 1, sacharinate, form I 2-theta d [Å] I/I0 [°] spacing [%] 5.77 15.31 17 7.80 11.32 11 8.09 10.91 13 8.65 10.21 20 8.95 9.87 13 9.35 9.45 17 9.97 8.86 17 11.24 7.86 64 11.58 7.63 21 12.04 7.34 36 12.27 7.20 25 12.81 6.90 52 13.34 6.63 58 14.41 6.14 23 14.99 5.90 85 15.61 5.67 64 16.24 5.45 20 16.72 5.30 85 17.22 5.14 100 17.84 4.97 22 18.20 4.87 18 18.75 4.73 30 19.18 4.62 64 20.04 4.43 44 20.77 4.27 24 21.15 4.20 28 21.66 4.10 15 22.41 3.96 22 22.73 3.91 26 23.29 3.81 28 23.72 3.75 52 24.40 3.64 62 25.15 3.54 37 25.46 3.49 24 25.77 3.45 23 26.26 3.39 22 26.77 3.33 55 27.43 3.25 18 28.14 3.17 21 28.37 3.14 29 28.68 3.11 24 29.37 3.04 16 29.79 3.00 18 29.97 2.98 18 -
TABLE 1.9 X-ray powder reflections and intensity (normalized) of Pho1 = phosphate, form I 2-theta d [Å] I/I0 [°] spacing [%] 5.59 15.79 100 6.12 14.42 18 6.77 13.04 36 7.30 12.10 17 7.65 11.54 15 8.35 10.58 16 9.25 9.55 24 10.00 8.83 24 10.47 8.44 17 10.86 8.14 20 11.19 7.90 60 11.90 7.43 28 11.98 7.38 22 12.10 7.30 35 13.90 6.37 28 14.70 6.02 28 15.86 5.58 22 16.34 5.42 23 16.77 5.28 27 17.10 5.18 40 17.50 5.06 89 18.65 4.75 26 19.50 4.55 27 19.79 4.48 29 20.57 4.31 37 21.00 4.23 27 21.77 4.08 6 22.15 4.01 32 22.38 3.97 38 23.30 3.81 36 23.68 3.75 54 23.89 3.72 35 24.54 3.62 26 25.03 3.55 16 25.36 3.51 27 25.88 3.44 20 26.84 3.32 14 27.36 3.26 15 27.89 3.19 18 28.16 3.17 22 28.50 3.13 20 29.18 3.06 13 30.37 2.93 14 -
TABLE 1.10a X-ray powder reflections and intensity (normalized) of Mae 1, maleate, form I 2-theta d [Å] I/I0 [°] spacing [%] 8.51 10.38 10 9.22 9.58 84 11.47 7.71 84 13.83 6.40 12 14.44 6.13 100 14.92 5.93 94 15.60 5.68 17 15.87 5.58 26 16.22 5.46 63 16.84 5.26 47 17.36 5.10 38 17.77 4.99 21 18.51 4.79 27 18.68 4.75 48 19.19 4.62 70 20.54 4.32 10 21.12 4.20 20 22.65 3.92 13 23.08 3.85 21 23.54 3.78 45 24.67 3.61 58 25.95 3.43 18 26.77 3.33 11 27.83 3.20 21 28.81 3.10 10 29.39 3.04 17 29.76 3.00 24 30.64 2.92 14 31.48 2.84 27 -
TABLE 1.10b X-ray powder reflections and intensity (normalized) of Mae 3, maleate, form III 2-theta d [Å] I/I0 [°] spacing [%] 6.56 13.46 39 8.56 10.32 13 9.99 8.84 24 11.28 7.84 13 12.22 7.23 32 13.10 6.75 26 13.85 6.38 44 14.58 6.07 52 16.20 5.47 16 16.76 5.28 45 17.16 5.16 100 17.46 5.07 31 18.50 4.79 18 19.24 4.61 18 19.62 4.52 91 20.08 4.42 43 20.41 4.35 27 21.00 4.22 9 21.65 4.10 58 22.23 4.00 42 22.73 3.91 21 22.90 3.88 22 23.27 3.82 40 23.90 3.72 39 24.28 3.66 40 24.86 3.58 10 25.30 3.52 41 25.66 3.47 27 26.57 3.35 23 27.14 3.28 38 27.82 3.20 64 28.55 3.12 17 29.14 3.06 14 29.48 3.03 19 29.70 3.00 13 30.73 2.91 35 -
TABLE 1.11 X-ray powder reflections and intensity (normalized) of Ets 1, ethanesulfonate, form I 2-theta d [Å] I/I0 [°] spacing [%] 5.77 15.30 62 6.97 12.66 14 7.82 11.29 15 9.70 9.11 10 11.55 7.65 29 12.19 7.25 40 13.04 6.78 17 14.16 6.25 31 14.42 6.14 14 15.69 5.64 21 15.97 5.54 33 16.46 5.38 9 16.80 5.27 9 17.18 5.16 13 17.70 5.00 56 17.94 4.94 20 18.97 4.67 21 19.45 4.56 15 20.06 4.42 32 20.46 4.34 52 20.98 4.23 100 21.54 4.12 15 22.83 3.89 12 23.38 3.80 26 24.06 3.69 18 25.18 3.53 27 25.61 3.47 37 26.00 3.42 21 26.34 3.38 12 26.85 3.31 11 27.78 3.21 37 28.34 3.15 9 -
TABLE 1.12 X-ray powder reflections and intensity (normalized) of Cas1 = camphorsulfonate, form I 2-theta d [Å] I/I0 [°] spacing [%] 5.41 16.32 100 9.60 9.20 9 10.07 8.77 10 10.79 8.19 14 11.38 7.77 7 12.26 7.21 11 12.34 7.17 12 13.15 6.72 8 13.86 6.38 12 14.10 6.27 21 15.55 5.69 30 16.10 5.50 45 16.25 5.45 52 16.62 5.33 11 16.79 5.29 11 17.59 5.04 15 17.79 4.98 20 18.65 4.75 18 19.32 4.59 19 20.21 4.39 19 20.96 4.23 10 21.49 4.13 18 21.73 4.08 17 22.50 3.95 17 23.06 3.85 17 23.58 3.78 17 23.95 3.71 16 24.55 3.62 24 25.07 3.55 13 28.65 3.11 9 29.10 3.07 7 29.18 3.06 6 -
TABLE 1.13 X-ray powder reflections and intensity (normalized) of Mao 1, malonate, form I 2-theta d [Å] I/I0 [°] spacing [%] 3.80 23.23 99 7.63 11.57 37 7.93 11.13 45 10.32 8.56 60 13.06 6.77 61 13.36 6.62 43 13.91 6.36 35 14.49 6.1 57 15.21 5.82 37 15.89 5.57 42 16.78 5.28 57 17.96 4.93 39 19.18 4.62 60 20.34 4.36 49 20.74 4.28 32 21.20 4.19 100 21.69 4.09 31 22.27 3.99 45 22.86 3.89 47 23.34 3.81 47 23.90 3.72 68 24.71 3.60 65 25.65 3.47 50 26.35 3.38 26 26.84 3.32 28 26.94 3.31 27 27.86 3.20 24 28.38 3.14 23 28.94 3.08 21 29.10 3.06 22 29.18 3.06 21 30.30 2.95 28 -
TABLE 1.14 X-ray powder reflections and intensity (normalized) of L-Tar 1, L-tartrate, form I 2-theta d [Å] I/I0 [°] spacing [%] 10.04 8.80 15 10.55 8.37 23 11.82 7.48 13 13.10 6.75 12 15.32 5.77 34, 15.94 5.55 20 16.22 5.46 59 17.17 5.16 11 17.92 4.94 67 18.55 4.78 44 19.05 4.65 30 19.61 4.52 17 20.18 4.40 14 20.64 4.30 73 21.23 4.18 45 21.74 4.08 99 23.08 3.85 17 23.76 3.74 100 24.31 3.66 9 25.23 3.53 28 25.88 3.44 17 26.46 3.36 11 27.27 3.27 42 27.55 3.23 23 28.29 3.15 12 28.76 3.10 9 29.08 3.07 11 30.46 2.93 13 30.87 2.89 15 -
TABLE 1.15a X-ray powder reflections and intensity (normalized) of Fum 1, fumarate, form I 2-theta d [Å] I/I0 [°] spacing [%] 8.51 10.38 18 9.13 9.68 31 10.35 8.54 37 11.11 7.95 12 11.39 7.76 13 12.07 7.32 20 13.87 6.38 39 14.54 6.08 23 15.30 5.79 35 15.57 5.68 28 16.15 5.48 23 17.07 5.19 42 17.75 4.99 22 18.19 4.87 61 18.53 4.78 20 18.76 4.72 28 19.78 4.48 2 20.77 4.27 34 21.44 4.14 13 21.92 4.05 23 22.92 3.88 24 23.91 3.72 100 24.27 3.66 33 24.69 3.60 21 25.24 3.52 14 25.77 3.45 45 26.24 3.39 14 27.17 3.28 18 27.71 3.22 10 -
TABLE 1.15b X-ray powder reflections and intensity (normalized) of Fum 2, fumerate, form II 2-theta d [Å] I/I0 [°] spacing [%] 10.20 8.66 30 10.84 8.15 18 11.89 7.43 25 13.29 6.66 16 15.19 5.83 40 15.81 5.60 14 16.32 5.42 64 18.07 4.90 36 18.74 4.73 87 19.17 4.63 18 19.41 4.57 15 19.94 4.45 15 20.13 4.41 15 20.53 4.32 25 20.90 4.25 49 21.54 4.12 40 21.85 4.06 85 23.07 3.85 14 23.92 3.72 100 25.39 3.50 36 27.41 3.25 39 27.78 3.21 17 28.76 3.10 12 29.23 3.05 14 30.99 2.88 12 32.95 2.72 15 33.80 2.65 11 36.61 2.45 12 39.21 2.29 10 -
TABLE 1.16 X-ray powder reflections and intensity (normalized) of Gly1 = glycolate, form I 2-theta d [Å] I/I0 [°] spacing [%] 4.75 18.58 13 5.26 16.79 13 5.98 14.76 35 7.42 11.91 20 10.49 8.43 87 11.55 7.65 23 12.02 7.35 27 13.17 6.71 14 13.72 6.45 26 14.62 6.05 19 15.38 5.75 20 16.12 5.49 25 17.11 5.18 36 17.62 5.03 54 17.92 4.94 31 18.44 4.81 29 19.07 4.65 25 19.38 4.57 23 19.78 4.48 93 20.82 4.26 22 21.09 4.21 27 21.90 4.05 34 22.41 3.96 100 22.59 3.93 91 23.21 3.83 18 23.76 3.74 71 24.18 3.68 24 24.26 3.66 24 24.53 3.62 28 24.90 3.57 19 25.40 3.50 21 25.83 3.45 17 26.64 3.34 17 27.27 3.27 14 27.71 3.22 22 28.06 3.18 15 28.34 3.15 17 28.69 3.11 14 29.48 3.03 8 29.98 2.98 16 30.36 2.94 20 -
TABLE 1.17 X-ray powder reflections and intensity (normalized) of Cit 1, citrate, form I 2-theta d [Å] I/I0 [°] spacing [%] 5.66 15.61 100 6.64 13.29 18 8.93 9.89 8 11.31 7.81 26 11.83 7.47 25 13.50 6.55 6 13.86 6.38 7 14.65 6.04 9 16.58 5.34 27 16.95 5.22 10 17.61 5.03 9 18.21 4.87 52 18.95 4.68 18 19.26 4.60 7 20.87 4.25 15 21.70 4.09 19 22.75 3.90 7 23.06 3.85 6 23.88 3.72 8 24.28 3.66 10 24.61 3.61 13 25.07 3.54 7 25.82 3.45 5 26.26 3.39 6 27.00 3.30 13 27.75 3.21 8 28.05 3.18 7 28.55 3.12 7 29.38 3.04 6 -
TABLE 1.18 X-ray powder reflections and intensity (normalized) of Man 1, mandelate, form I 2-theta d [Å] I/I0 [°] spacing [%] 7.42 11.90 9 8.35 10.57 29 10.57 8.36 26 12.00 7.36 16 12.32 7.17 10 14.08 6.28 30 14.74 6.00 15 15.29 5.79 11 15.69 5.64 32 16.34 5.42 14 16.67 5.31 11 17.34 5.11 13 18.19 4.87 100 18.56 4.78 18 19.01 4.66 63 19.69 4.50 23 20.08 4.42 31 21.05 4.22 12 21.41 4.14 26 21.66 4.10 36 22.08 4.02 21 22.89 3.88 37 23.54 3.77 28 23.86 3.73 41 24.41 3.64 23 24.81 3.58 10 25.23 3.53 14 26.09 3.41 4 26.47 3.36 12 -
TABLE 1.19 X-ray powder reflections and intensity (normalized) of L-Mal 1, malate, form I 2-theta d [Å] I/I0 [°] spacing [%] 8.40 10.51 9 11.30 7.82 71 11.69 7.56 12 12.49 7.08 11 12.75 6.94 10 13.38 6.61 10 13.68 6.47 10 14.49 6.10 59 14.80 5.98 16 15.09 5.87 32 15.78 5.61 28 16.96 5.22 47 17.89 4.95 48 18.27 4.85 36 18.90 4.69 12 19.63 4.52 38 20.48 4.33 9 21.36 4.15 24 21.98 4.04 11 22.69 3.91 32 23.46 3.79 100 23.91 3.72 62 24.19 3.68 24 24.23 3.67 26 24.91 3.57 35 25.38 3.50 19 26.14 3.41 12 26.64 3.34 27 27.33 3.26 9 -
TABLE 1.20 X-ray powder reflections and intensity (normalized) of Nas1 = naphtalene-sulfonate, form I 2-theta d [Å] I/I0 [°] spacing [%] 3.17 27.83 17 12.71 6.95 11 12.93 6.84 9 13.97 6.33 25 14.14 6.26 24 14.44 6.13 20 14.83 5.96 20 15.06 5.88 11 15.89 5.57 40 17.64 5.02 46 18.02 4.92 100 18.33 4.83 29 19.05 4.65 43 19.43 4.56 31 20.51 4.32 14 21.69 4.09 11 22.17 4.00 59 22.41 3.96 53 23.22 3.83 25 23.99 3.70 9 25.58 3.48 13 25.88 3.43 63 26.57 3.35 11 26.80 3.32 12 27.07 3.29 25 27.37 3.25 27 28.18 3.16 16 29.01 3.07 7 29.64 3.01 10 29.95 2.98 10 30.47 2.93 8 31.57 2.83 10 33.33 2.69 8 35.92 2.50 10 36.96 2.43 8 -
TABLE 1.21 X-ray powder reflections and intensity (normalized) of Tos 2, tosylate, form II 2-theta d [Å] I/I0 [°] spacing [%] 4.89 18.04 20 6.29 14.03 6 7.91 11.16 5 10.59 8.35 13 12.64 7.00 8 12.89 6.86 10 13.78 6.42 4 14.75 6.00 4 15.43 5.74 20 15.76 5.62 4 16.79 5.28 5 17.21 5.15 7 17.96 4.94 100 18.73 4.73 10 19.01 4.67 4 19.39 4.57 24 19.97 4.44 11 20.53 4.32 47 20.85 4.26 10 21.27 4.17 4 21.77 4.08 6 22.10 4.02 6 22.76 3.90 3 23.07 3.85 3 23.97 3.71 11 24.48 3.63 6 24.91 3.57 4 25.19 3.53 21 25.95 3.43 4 26.61 3.35 43 -
TABLE 1.22 X-ray powder reflections and intensity (normalized) of Tos 2, fumarate, form III 2-theta d [Å] I/I0 [°] spacing [%] 9.64 9.17 68 10.65 8.30 3 11.53 7.67 5 12.41 7.13 3 14.39 6.15 19 15.15 5.84 30 15.87 5.58 26 16.61 5.33 92 17.01 5.21 96 17.83 4.97 44 18.84 4.71 66 19.37 4.58 18 19.59 4.53 80 19.89 4.46 77 20.33 4.36 33 20.79 4.27 14 21.55 4.12 86 21.97 4.04 19 22.82 3.89 7 23.55 3.78 26 24.07 3.69 100 24.49 3.63 17 25.03 3.55 28 27.40 3.25 14 28.11 3.17 18 28.37 3.14 11 -
TABLE 1.23 X-ray powder reflections and intensity (normalized) of Cas 2, camphorsulfonate,, form II 2-theta d [Å] I/I0 [°] spacing [%] 5.27 16.75 29 6.69 13.20 10 7.01 12.61 12 8.09 10.92 9 9.63 9.18 15 10.03 8.81 6 10.57 8.36 8 12.27 7.21 19 14.08 6.29 28 14.48 6.11 26 15.04 5.89 11 15.55 5.69 15 16.18 5.47 100 16.29 5.44 99 17.23 5.14 16 17.62 5.03 14 17.74 4.99 10 18.63 4.76 53 19.21 4.62 12 19.48 4.55 12 19.88 4.46 45 20.05 4.42 28 20.44 4.34 22 20.56 4.32 20 21.27 4.17 37 22.12 4.01 17 23.32 3.81 22 24.03 3.70 35 24.63 3.61 30 25.25 3.52 11 -
TABLE 1.24 X-ray powder reflections and intensity (normalized) of Gly 2, glycolate,, form II 2-theta d [Å] I/I0 [°] spacing [%] 9.98 8.86 12 10.47 8.44 13 10.98 8.05 7 11.25 7.86 5 11.62 7.61 15 12.65 7.00 14 13.05 6.78 30 13.85 6.39 9 14.18 6.24 4 14.57 6.07 4 15.40 5.75 40 15.59 5.68 24 16.03 5.53 11 16.19 5.47 13 16.61 5.33 5 17.30 5.12 18 17.73 5.00 13 18.11 4.89 8 18.38 4.82 15 18.67 4.75 13 19.10 4.64 34 19.77 4.49 21 20.02 4.43 31 20.34 4.36 22 21.12 4.20 15 21.61 4.11 18 22.09 4.02 100 22.38 3.97 78 23.21 3.83 15 23.56 3.77 13 - The single crystal data and structure refinement for the crystalline salt forms in accordance with the present invention are displayed In the preceding tables 2.1 to 2.18. The abbreviations used in those tables have the following meanings:
- Fw=formula weight;
T=Temperature of data collection;
π=wavelength of X-ray source;
Dm=calculated density;
θ range=Theta range of data collection; -
R[I>2σ(I)]=Final R indices [I>2sigma(I)] -
TABLE 2.1 Single crystal data and structure refinement of bromide form III Empirical formula C20H22F3N4O+•Br—•0.5 H2O•0.5 CH3OH Fw 496.35 T [K] 120(2) λ[Å] 0.71073 Crystal system Monoclinic Space group P 21/c Unit cell dimensions a [Å] 6.9150(3) b [Å] 30.801(2) c [Å] 20.4990(8) α [°] 90 β [°] 95.728(2) γ [°] 90 V [Å3] 4344.3 (3)(1) Z 4 Dm [g/cm3] 1.518 F(000) 2032 Crystal size [mm3] 0.30 × 0.20 × 0.06 θ range [°] 2 → 27.5 Reflections collected 9029 Independent reflections 6180 [Rint = 0.0424] S 1.15 R [I > 2σ(I)] R1 = 0.0605, wR2 = 0.1329 R indices (all data) R1 = 0.0766, wR2 = 0.1423 -
TABLE 2.2 Single crystal data and structure refinement of oxalate form I Empirical formula C20H22F3N4O•C2HO4 Fw 480.44 T [K] 293(2) λ[Å] 0.71073 Å Crystal system Orthorhombic Space group P 212121 Unit cell dimensions a [Å] 10.3900(4) b [Å] 11.3420(4) c [Å] 19.3230(6) α [°] 90 β [°] 90 γ [°] 90 V [Å3] 2277.1(2) Z 4 Dm [g/cm3] 1.401 F(000) 1000 Crystal size [mm3] 0.3 × 0.25 × 0.2 θ range [°] 3 → 27.5 Reflections collected 14241 Independent reflections 5179 [Rint = 0.0243] S 1.058 R [I > 2σ(I)] R1 = 0.0379, wR2 = 0.0808 R indices (all data) R1 = 0.0465, wR2 = 0.0856 -
TABLE 2.3 Single crystal data and structure refinement of oxalate form V Empirical formula C20H22F3N4O+•0.5 C2O4 2−•H2O Fw 453.44 T [K] 120(2) λ[Å] 0.71073 Crystal system Monoclinic Space group P 21/c Unit cell dimensions a [Å] 7.6030(3) b [Å] 28.5050(10) c [Å] 10.6200(4) α [°] 90 β [°] 113.346(2) γ [°] 90 V [Å3] 2113.17(14) Z 4 Dm [g/cm3] 1.425 F(000) 948 Crystal size [mm3] 0.2 × 0.15 × 0.1 θ range [°] 1.5 → 24. Reflections collected 10041 Independent reflections 3302 [Rint = 0.0791] S 4.655 R [I > 2σ(I)] R1 = 0.2415, wR2 = 0.5590 R indices (all data) R1 = 0.2468, wR2 = 0.5629 -
TABLE 2.4 Single crystal data and structure refinement of sacharinate form I Empirical formula C20H22F3N4O+•C7H4NSO3 −•1.5 H2O Fw 600.61 T [K] 293(2) λ[Å] 0.71073 Crystal system Triclinic Space group P −1 Unit cell dimensions a [Å] 8.1930(2) b [Å] 11.7200(2) c [Å] 30.7140(7) α [°] 93.206(1) β [°] 92.430(1) γ [°] 103.257(1) V [Å3] 2861.5(2) Z 4 Dm [g/cm3] 1.394 F(000) 1252 Crystal size [mm3] 0.4 × 0.35 × 0.2 θ range [°] 2 → 25.5 Reflections collected 15887 Independent reflections 10288 [Rint = 0.0372] S 1.078 R [I > 2σ(I)] R1 = 0.0686, wR2 = 0.1316 R indices (all data) R1 = 0.1218, wR2 = 0.1551 -
TABLE 2.5 Single crystal data and structure refinement of maleate form I Empirical formula C20H22F3N4O+•C4H3O4 −•C4H8O Fw 578.58 T [K] 293(2) λ[Å] 0.71073 Crystal system Orthorhombic Space group Pbca Unit cell dimensions a [Å] 19.9300(1) b [Å] 12.2540(2) c [Å] 24.2320(3) α [°] 90 β [°] 90 γ [°] 90 V [Å3] 5917.99(12) Z 8 Dm [g/cm3] 1.299 F(000) 2432 Crystal size [mm3] 0.3 × 0.2 × 0.1 θ range [°] 1.7 → 25 Reflections collected 35074 Independent reflections 5199 [Rint = 0.0461] S 1.107 R [I > 2σ(I)] R1 = 0.0625, wR2 = 0.1701 R indices (all data) R1 = 0.0808, wR2 = 0.1901 -
TABLE 2.6 Single crystal data and structure refinement of maleate form III Empirical formula C20H22F3N4O+•C4H3O4 Fw 506.48 T [K] 293(2) K λ[Å] 0.71073 Crystal system Monoclinic Space group C 2/c Unit cell dimensions a [Å] 27.2820(5) b [Å] 8.1960(2) c [Å] 20.8440(4) α [°] 90 β [°] 98.295(1) γ [°] 90 V [Å3] 4612.03(13) Z 8 Dm [g/cm3] 1.459 F(000) 2112 Crystal size [mm3] 0.35 × 0.2 × 0.1 θ range [°] 2.5 → 30 Reflections collected 11604 Independent reflections 6688 [Rint = 0.0242] S 1.023 R [I > 2σ(I)] R1 = 0.0504, wR2 = 0.1108 R indices (all data) R1 = 0.0680, wR2 = 0.1219 -
TABLE 2.7 Single crystal data and structure refinement of ethanesulfonate form I Empirical formula C20H22F3N4O+•C2H5SO3 −•H2O Fw 518.55 T [K] 293(2) K λ[Å] 0.71073 Crystal system Monoclinic Space group P 21/c Unit cell dimensions a [Å] 15.3580(2) b [Å] 22.6680(7) c [Å] 7.0870(6) α [°] 90 β [°] 91.595(2) γ [°] 90 V [Å3] 2466.3(2) Z 4 Dm [g/cm3] 1.397 Mg/m3 F(000) 1088 Crystal size [mm3] 0.3 × 0.2 × 0.2 θ range [°] 2 → 26 Reflections collected 11237 Independent reflections 4736 [Rint = 0.0409] S 1.033 R [I > 2σ(I)] R1 = 0.0598, wR2 = 0.1222 R indices (all data) R1 = 0.0935, wR2 = 0.1389 -
TABLE 2.8 Single crystal data and structure refinement of malonate form I Empirical formula C20H22F3N4O+•C3H3O4 −•2H2O Fw 530.50 T [K] 293(2) λ[Å] 0.71073 Crystal system Monoclinic Space group P 21/c Unit cell dimensions a [Å] 23.2150(2) b [Å] 12.7050(2) c [Å] 8.3990(4) α [°] 90 β [°] 92.422(1) γ [°] 90 V [Å3] 2475.0(2) Z 4 Dm [g/cm3] 1.424 Mg/m3 F(000) 1112 Crystal size [mm3] 0.45 × 0.4 × 0.3 θ range [°] 2 → 26 Reflections collected 8896 Independent reflections 4849 [Rint = 0.0207] S 1.033 R [I > 2σ(I)] R1 = 0.0456, wR2 = 0.1076 R indices (all data) R1 = 0.0595, wR2 = 0.1165 -
TABLE 2.9 a) Single crystal data and structure refinement of malonate form II Empirical formula C20H22F3NO+•C3H3O4 −2•2 C4H10O Fw 642.71 T [K] 120(2) λ[Å] 0.71073 Crystal system Monoclinic Space group P 21/c Unit cell dimensions a [Å] 9.2650(3) b [Å] 24.2380(2) c [Å] 30.128(8) α [°] 90 β [°] 101.620(2) γ [°] 90 V [Å3] 6627.0(4) Z 8 Dm [g/cm3] 1.288 F(000) 2736 Crystal size [mm3] 0.25 × 0.1 × 0.08 θ range [°] 1.5 → 24 Reflections collected 22364 Independent reflections 10286 [Rint = 0.1143] S 1.093 R [I > 2σ(I)] R1 = 0.1070, wR2 = 0.1271 R indices (all data) R1 = 0.2167, wR2 = 0.1563 -
TABLE 2.9 b) Atomic coordinates and temperature factor (Uiso) of malonate form II atom x y z U iso O1 0.06149(5) 0.95243(10) 0.12162(17) 0.0575(4) C2 0.06563(7) 1.04882(15) 0.1421(2) 0.0460(4) N3 0.02959(7) 1.12484(13) 0.0841(2) 0.0534(4) H3 0.0000 11.075 0.013 0.05 C4 0.05036(8) 1.22360(15) 0.1289(2) 0.0483(4) C5 0.03015(10) 1.32383(17) 0.0973(3) 0.0630(5) H5 −0.0037 13.353 0.0364 0.05 C6 0.06249(11) 1.40672(17) 0.1605(3) 0.0694(6) H6 0.0501 14.753 0.1412 0.05 C7 0.11273(10) 1.39022(17) 0.2513(3) 0.0653(6) H7 0.1334 14.478 0.2912 0.05 C8 0.13280(9) 1.28983(16) 0.2841(2) 0.0546(5) H8 0.1665 12.785 0.3453 0.05 C9 0.10068(7) 1.20725(14) 0.22200(19) 0.0428(4) N10 0.10868(6) 1.09832(11) 0.23008(17) 0.0429(3) C11 0.15342(7) 1.04136(15) 0.3200(2) 0.0433(4) H11A 0.1395 0.9719 0.3469 0.05 H11B 0.1632 10.785 0.4183 0.05 C12 0.20654(7) 1.03133(14) 0.22173(18) 0.0389(4) H12A 0.1957 10.007 0.119 0.05 H12B 0.2223 11.008 0.2033 0.05 N13 0.25191(5) 0.96389(10) 0.30396(15) 0.0334(3) H13 0.2547 0.9800 0.411 0.05 C14 0.23667(7) 0.84980(13) 0.2895(2) 0.0397(4) H14A 0.2288 0.833 0.1781 0.05 H14B 0.2017 0.8368 0.3457 0.05 C15 0.28364(7) 0.77827(14) 0.3555(2) 0.0420(4) H15A 0.2891 0.7896 0.4694 0.05 H15B 0.2725 0.7054 0.3384 0.05 N16 0.33750(6) 0.79918(10) 0.27768(16) 0.0380(3) C17 0.35469(7) 0.90831(13) 0.3045(2) 0.0416(4) H17A 0.391 0.9214 0.2552 0.05 H17B 0.3602 0.921 0.4181 0.05 C18 0.30930(7) 0.98259(13) 0.2356(2) 0.0395(4) H18A 0.3212 10.546 0.257 0.05 H18B 0.306 0.9734 0.1209 0.05 C19 0.38090(7) 0.72145(13) 0.28732(18) 0.0372(4) C20 0.43295(7) 0.73712(14) 0.2127(2) 0.0437(4) H20 0.4394 0.8002 0.1602 0.05 C21 0.47493(8) 0.65993(15) 0.2160(2) 0.0491(4) C22 0.52955(9) 0.67841(19) 0.1321(3) 0.0676(6) F23 0.54009(8) 0.77815(16) 0.0996(3) 0.1027(7) F24 0.57558(6) 0.64307(19) 0.2129(3) 0.1119(7) F25 0.52921(11) 0.6298(3) −0.0085(3) 0.1296(9) F1 0.5567(8) 0.5924(14) 0.126(2) 0.089(5) F2 0.5243(8) 0.6933(16) −0.003(2) 0.083(5) F3 0.5524(8) 0.7631(16) 0.188(2) 0.081(5) C26 0.46634(9) 0.56455(15) 0.2925(2) 0.0573(5) H26 0.4947 0.5128 0.2949 0.05 C27 0.41504(9) 0.54833(15) 0.3645(2) 0.0571(5) H27 0.4086 0.4847 0.4154 0.05 C28 0.37289(8) 0.62526(14) 0.3624(2) 0.0462(4) H28 0.3385 0.6125 0.4121 0.05 O31 0.25950(6) 0.98586(10) 0.62415(13) 0.0515(3) C32 0.28074(7) 1.05416(13) 0.71758(18) 0.0390(4) O33 0.26985(6) 1.05918(9) 0.86187(13) 0.0486(3) C34 0.32323(7) 1.13283(13) 0.65329(19) 0.0417(4) H34A 0.3411 11.716 0.7417 0.05 H34B 0.3534 10.949 0.6009 0.05 C35 0.29546(8) 1.20947(13) 0.53724(19) 0.0425(4) O36 0.2674(4) 1.1813(6) 0.4212(7) 0.0620(17) O36 0.2496(4) 1.1918(7) 0.4706(10) 0.120(3) O37 0.31592(7) 1.30312(10) 0.54566(16) 0.0606(4) H37 0.2947 1.352 0.464 0.05 O40 0.13507(9) 0.68241(17) 0.4657(2) 0.0836(5) H40A 0.1390 0.744 0.528 0.05 H40B 0.1122 0.639 0.520 0.05 O41 0.16352(9) 0.85416(13) 0.6539(2) 0.0708(4) H41A 0.1533 0.848 0.747 0.05 H41B 0.1949 0.906 0.666 0.05 (hydrogen atoms were calculated according to well-established geometrical criteria) -
TABLE 2.10 a) Single crystal data and structure refinement of malonate form VI Empirical formula C20H22F3N4O+•C3H3O4 −2•H2O Fw 530.50 T [K] 120(2) λ[Å] 0.71073 Crystal system Triclinic Space group P −1 Unit cell dimensions a [Å] 7.8050(2) b [Å] 8.0730(2) c [Å] 20.1470(4) α [°] 80.0090(8) β [°] 87.4660(8) γ [°] 74.5320(9) V [Å3] 1204.92(3) Z 2 Dm [g/cm3] 1.462 F(000) 556 Crystal size [mm3] 0.3 × 0.25 × 0.1 θ range [°] 2 → 37 Reflections collected 14593 Independent reflections 12114 [Rint = 0.0408] S 1.062 R [I > 2σ(I)] R1 = 0.0742, wR2 = 0.1389 R indices (all data) R1 = 0.1184, wR2 = 0.1594 -
TABLE 2.10 b) Atomic coordinates and temperature factor (Uiso) of malonate form VI atom x y z U (iso) O1A 0.6256(4) 0.27887(16) 0.17045(13) 0.0277(11) C2A 0.5192(7) 0.2652(3) 0.1409(2) 0.0212(15) N3A 0.4241(5) 0.29908(19) 0.11247(15) 0.0212(12) H3A 0.4286 0.3353 0.1127 0.02 C4A 0.3190(6) 0.2679(2) 0.0831(2) 0.0179(14) C5A 0.2037(6) 0.2833(3) 0.04897(19) 0.0242(16) H5A 0.1833 0.3211 0.0418 0.02 C6A 0.1185(6) 0.2416(3) 0.0255(2) 0.0294(17) H6A 0.0385 0.2508 0.0016 0.02 C7A 0.1483(6) 0.1864(3) 0.0364(2) 0.0294(17) H7A 0.0876 0.1587 0.0199 0.02 C8A 0.2654(6) 0.1710(3) 0.07092(19) 0.0262(16) H8A 0.2868 0.1334 0.078 0.02 C9A 0.3485(6) 0.2127(2) 0.09428(19) 0.0190(15) N10A 0.4703(5) 0.21199(19) 0.13030(15) 0.0204(12) C11A 0.5469(5) 0.1621(2) 0.14896(18) 0.0172(14) H11A 0.6436 0.1728 0.1675 0.02 H11B 0.5659 0.1392 0.1236 0.02 C12A 0.4662(6) 0.1273(2) 0.17793(18) 0.0172(14) H12A 0.3589 0.1304 0.1659 0.02 H12B 0.494 0.0882 0.1753 0.02 N13A 0.4970(4) 0.14286(18) 0.22701(14) 0.0165(11) H13A 0.5969 0.1372 0.2383 0.02 C14A 0.4135(6) 0.1054(2) 0.25244(19) 0.0238(15) H14A 0.4441 0.0668 0.2488 0.02 H14B 0.3069 0.1083 0.2392 0.02 C15A 0.4389(6) 0.1192(2) 0.30237(19) 0.0226(15) H15A 0.3777 0.0948 0.3175 0.02 H15B 0.5436 0.1128 0.3165 0.02 N16A 0.4004(5) 0.17688(19) 0.30840(15) 0.0199(12) C17A 0.4908(6) 0.2133(2) 0.28613(19) 0.0223(15) H17A 0.5963 0.2075 0.2996 0.02 H17B 0.4664 0.2523 0.2912 0.02 C18A 0.4638(6) 0.2019(2) 0.23563(18) 0.0184(14) H18A 0.3598 0.21 0.2218 0.02 H18B 0.5272 0.2262 0.2214 0.02 C19A 0.3798(5) 0.1932(2) 0.35192(19) 0.0182(14) C20A 0.3480(5) 0.2486(2) 0.3594(2) 0.0200(15) H20A 0.3438 0.2749 0.3358 0.02 C21A 0.3225(6) 0.2651(2) 0.40129(19) 0.0187(14) C22A 0.2861(7) 0.3240(3) 0.4078(2) 0.0254(16) F23A 0.3146(4) 0.35757(15) 0.37532(12) 0.0509(11) F24A 0.1446(4) 0.33182(15) 0.40826(14) 0.0566(12) F25A 0.3606(4) 0.34482(15) 0.44665(12) 0.0541(12) C26A 0.3277(6) 0.2278(3) 0.4358(2) 0.0262(16) H26A 0.3117 0.2395 0.4646 0.02 C27A 0.3561(7) 0.1734(3) 0.4284(2) 0.0358(18) H27A 0.3561 0.1472 0.4519 0.02 C28A 0.3849(6) 0.1560(2) 0.3871(2) 0.0284(16) H28A 0.4082 0.1185 0.383 0.02 O31A 0.7669(4) 0.04516(16) 0.26795(14) 0.0319(11) C32A 0.8398(6) 0.0894(3) 0.27126(19) 0.0209(15) O33A 0.7893(4) 0.13579(16) 0.25753(13) 0.0282(11) C34A 1.0035(5) 0.0870(2) 0.29359(19) 0.0203(15) H34A 1.061 0.0976 0.2706 0.02 H34B 1.0222 0.1154 0.3177 0.02 C35A 1.0641(7) 0.0322(2) 0.3144(2) 0.0245(16) O36A 0.9790(4) −0.01052(16) 0.30492(15) 0.0352(12) H36A 0.8956 −0.0003 0.2908 0.02 O37A 1.1868(4) 0.02969(16) 0.33793(14) 0.0333(12) O41A 1.2576(4) −0.05443(17) 0.40344(13) 0.0288(11) H41A 1.2167 −0.0332 0.3826 0.02 C42A 1.2321(6) −0.0346(3) 0.4464(2) 0.0277(16) C43A 1.2648(7) 0.0266(3) 0.4509(2) 0.047(2) H43A 1.3679 0.0332 0.4492 0.02 H43B 1.2471 0.0399 0.4801 0.02 H43C 1.2004 0.0465 0.4262 0.02 C44A 1.3404(7) −0.0664(3) 0.4820(2) 0.045(2) H44A 1.4413 −0.0583 0.4787 0.02 H44B 1.3216 −0.1061 0.478 0.02 H44C 1.328 −0.0554 0.5123 0.02 C45A 1.0738(7) −0.0465(3) 0.4494(2) 0.058(2) H45A 1.0073 −0.0258 0.4258 0.02 H45B 1.0573 −0.0353 0.4793 0.02 H45C 1.0544 −0.0861 0.4452 0.02 O51A 1.5312(4) −0.08854(17) 0.39215(14) 0.0309(11) H51A 1.4456 −0.0785 0.3938 0.02 C52A 1.5851(6) −0.0545(3) 0.3599(2) 0.0286(16) C53A 1.6192(7) 0.0023(2) 0.3799(2) 0.051(2) H53A 1.5276 0.0201 0.3838 0.02 H53B 1.6655 0.0245 0.3595 0.02 H53C 1.6864 −0.0009 0.4094 0.02 C54A 1.7245(6) −0.0836(3) 0.3520(2) 0.0405(19) H54A 1.6987 −0.1202 0.339 0.02 H54B 1.7946 −0.0875 0.3809 0.02 H54C 1.7695 −0.0617 0.331 0.02 C55A 1.4715(7) −0.0522(3) 0.3158(2) 0.049(2) H55A 1.3826 −0.0334 0.321 0.02 H55B 1.4464 −0.0897 0.3049 0.02 H55C 1.5123 −0.0318 0.2931 0.02 O1B 0.1417(4) 0.19068(16) 0.17087(13) 0.0252(10) C2B 0.0323(6) 0.2013(2) 0.1414(2) 0.0198(15) N3B −0.0561(5) 0.16559(19) 0.11321(15) 0.0209(12) H3B −0.0436 0.1296 0.1133 0.02 C4B −0.1687(6) 0.1934(2) 0.08423(18) 0.0188(15) C5B −0.2809(6) 0.1751(3) 0.05088(18) 0.0236(15) H5B −0.2934 0.137 0.0434 0.02 C6B −0.3765(6) 0.2155(3) 0.02831(19) 0.0258(16) H6B −0.4561 0.2045 0.0049 0.02 C7B −0.3584(6) 0.2715(3) 0.03916(19) 0.0241(16) H7B −0.425 0.2977 0.0229 0.02 C8B −0.2446(6) 0.2893(2) 0.07324(18) 0.0193(14) H8B −0.2318 0.3272 0.0808 0.02 C9B −0.1505(6) 0.2498(2) 0.09576(18) 0.0146(14) N10B −0.0273(5) 0.25355(18) 0.13118(15) 0.0172(12) C11B 0.0424(6) 0.3050(2) 0.14887(18) 0.0216(15) H11C 0.0595 0.3277 0.1231 0.02 H11D 0.1399 0.2964 0.168 0.02 C12B −0.0455(6) 0.3390(2) 0.17676(17) 0.0180(14) H12C −0.0201 0.3784 0.1744 0.02 H12D −0.1518 0.3347 0.1636 0.02 N13B −0.0190(5) 0.32326(18) 0.22561(15) 0.0171(12) H13B 0.0805 0.3287 0.2378 0.02 C14B −0.1054(6) 0.3604(2) 0.25018(18) 0.0216(15) H14C −0.2115 0.3571 0.2365 0.02 H14D −0.0755 0.3992 0.2467 0.02 C15B −0.0812(6) 0.3463(2) 0.29995(19) 0.0237(16) H15C 0.0236 0.3521 0.3142 0.02 H15D −0.1418 0.3708 0.315 0.02 N16B −0.1215(4) 0.28845(19) 0.30597(15) 0.0187(12) C17B −0.0337(6) 0.2518(2) 0.28316(17) 0.0192(14) H17C −0.0624 0.2131 0.2872 0.02 H17D 0.0718 0.2559 0.2974 0.02 C18B −0.0546(6) 0.2643(2) 0.23363(18) 0.0169(14) H18C −0.158 0.2566 0.2188 0.02 H18D 0.0099 0.2399 0.2198 0.02 C19B −0.1474(6) 0.2726(2) 0.34842(19) 0.0190(15) C20B −0.1114(6) 0.2197(2) 0.36562(19) 0.0224(15) H20B −0.0582 0.1955 0.35 0.02 C21B −0.1516(6) 0.2022(3) 0.4048(2) 0.0267(16) C22B −0.1134(9) 0.1451(3) 0.4220(2) 0.0395(19) F23B −0.0087(9) 0.1436(3) 0.4596(3) 0.083(3) F24B −0.2331(9) 0.1182(3) 0.4324(3) 0.084(3) F25B 0.0721(10) 0.1111(2) 0.39188(19) 0.072(2) F23B 0.0097(19) 0.1262(8) 0.4107(7) 0.045(6) F24B −0.083(2) 0.1414(10) 0.4649(9) 0.042(7) F25B −0.211(3) 0.1131(12) 0.4113(8) 0.068(9) C26B −0.2274(6) 0.2364(3) 0.4293(2) 0.0284(16) H26B −0.2571 0.2236 0.4559 0.02 C27B −0.2578(6) 0.2894(3) 0.4136(2) 0.0293(16) H27B −0.3057 0.3141 0.4305 0.02 C28B −0.2202(5) 0.3075(2) 0.37391(19) 0.0223(15) H28C −0.244 0.3441 0.3637 0.02 O31B 0.6664(4) 0.43895(16) 0.33478(13) 0.0302(11) C32B 0.5421(7) 0.4349(2) 0.3115(2) 0.0221(15) O33B 0.4540(4) 0.47697(16) 0.30146(13) 0.0276(11) C34B 0.4840(6) 0.3795(2) 0.29294(19) 0.0213(15) H34C 0.5031 0.3526 0.3182 0.02 H34D 0.5424 0.3677 0.2705 0.02 C35B 0.3212(6) 0.3755(3) 0.27050(19) 0.0196(15) O36B 0.2732(4) 0.32836(16) 0.25941(13) 0.0249(10) O37B 0.2453(4) 0.41894(16) 0.26514(14) 0.0278(11) H37B 0.2978 0.4458 0.2761 0.02 O41B 0.7322(4) 0.51862(16) 0.40487(12) 0.0286(11) H41B 0.7136 0.497 0.3827 0.02 C42B 0.7157(7) 0.4897(3) 0.4455(2) 0.0312(17) C43B 0.7507(8) 0.5326(3) 0.4831(2) 0.062(2) H43C 0.6785 0.5626 0.4771 0.02 H43D 0.8497 0.5474 0.4842 0.02 H43E 0.7466 0.5153 0.5122 0.02 C44B 0.5603(7) 0.4701(4) 0.4409(2) 0.089(3) H44C 0.5383 0.443 0.4163 0.02 H44D 0.4928 0.5015 0.434 0.02 H44E 0.5479 0.4529 0.4694 0.02 C45B 0.8230(8) 0.4422(3) 0.4545(3) 0.073(3) H45C 0.8004 0.4156 0.4296 0.02 H45D 0.8146 0.4241 0.483 0.02 H45E 0.9236 0.4561 0.4568 0.02 O51B 1.0131(4) 0.55326(16) 0.39488(13) 0.0263(10) H51B 0.9303 0.5415 0.3979 0.02 C52B 1.0615(6) 0.5226(2) 0.3591(2) 0.0261(16) C53B 1.0829(7) 0.4625(2) 0.3718(2) 0.0386(18) H53C 0.9879 0.4462 0.3741 0.02 H53D 1.1514 0.4593 0.4011 0.02 H53E 1.1233 0.443 0.3486 0.02 C54B 1.2073(6) 0.5495(3) 0.3542(2) 0.046(2) H54C 1.1901 0.5884 0.3458 0.02 H54D 1.2467 0.5304 0.3306 0.02 H54E 1.2781 0.547 0.383 0.02 C55B 0.9471(7) 0.5300(3) 0.3152(2) 0.0400(18) H55C 0.8535 0.5135 0.3188 0.02 H55D 0.9818 0.5118 0.2903 0.02 H55E 0.9329 0.5694 0.3086 0.02 (hydrogen atoms were calculated according to well-established geometrical criteria) -
TABLE 2.11 a) Single crystal data and structure refinement of salicylate form I Empirical formula C20H22F3N4O+•C7H5O3 − Fw 528.53 T [K] 293(2) λ[Å] 0.71073 Crystal system Monoclinic Space group P 21/c Unit cell dimensions a [Å] 16.3790(2) b [Å] 15.4410(4) c [Å] 10.1810(4) α [°] 90 β [°] 98.1820(12) γ [°] 90 V [Å3] 2548.6(2) Z 4 Dm [g/cm3] 1.377 F(000) 1104 Crystal size [mm3] 0.4 × 0.3 × 0.2 θ range [°] 2.5 → 26 Reflections collected 12472 Independent reflections 4948 [Rint = 0.0289] S 0.949 R [I > 2σ(I)] R1 = 0.0565, wR2 = 0.1471 R indices (all data) R1 = 0.0753, wR2 = 0.1647 -
TABLE 2.11 b) Atomic coordinates and temperature factor (Uiso) of salicylate, form I atom x y z U (iso) O1 0.91497(11) 0.00803(11) 0.86442(19) 0.0872(6) C2 0.92301(13) 0.08333(15) 0.9039(2) 0.0671(6) N3 0.97769(12) 0.11514(13) 1.0059(2) 0.0722(6) H3 1.0131(17) 0.0818(18) 1.054(3) 0.084(8) C4 0.96828(12) 0.20377(15) 1.0166(2) 0.0624(5) C5 1.00965(14) 0.26490(17) 1.0998(3) 0.0744(7) H5 10.514 0.2491 11.672 0.08 C6 0.98680(16) 0.35012(18) 1.0790(3) 0.0828(7) H6 1.014 0.3928 11.329 0.08 C7 0.92424(17) 0.37350(17) 0.9796(3) 0.0824(7) H7 0.9107 0.4317 0.9676 0.08 C8 0.88124(15) 0.31250(15) 0.8975(3) 0.0709(6) H8 0.8385 0.3283 0.8317 0.08 C9 0.90464(12) 0.22768(14) 0.9177(2) 0.0590(5) N10 0.87721(10) 0.15220(12) 0.85117(18) 0.0616(5) C11 0.81040(12) 0.14457(15) 0.7420(2) 0.0611(5) H11A 0.8186 0.0935 0.6899 0.08 H11B 0.8098 0.1949 0.6848 0.08 C12 0.72893(12) 0.13770(14) 0.7952(2) 0.0567(5) H12A 0.7233 0.0798 0.8296 0.08 H12B 0.7288 0.1781 0.8681 0.08 N13 0.65689(9) 0.15639(10) 0.69194(15) 0.0456(4) H13 0.6660 0.2124 0.660 0.08 C14 0.65126(12) 0.09592(12) 0.57744(19) 0.0521(5) H14A 0.646 0.0371 0.6084 0.08 H14B 0.7015 0.0995 0.5375 0.08 C15 0.57810(12) 0.11730(13) 0.47439(19) 0.0530(5) H15A 0.5866 0.1736 0.4363 0.08 H15B 0.5742 0.0748 0.4036 0.08 N16 0.50127(9) 0.11822(9) 0.53024(14) 0.0463(4) C17 0.50607(12) 0.17499(14) 0.6462(2) 0.0553(5) H17A 0.4555 0.1702 0.685 0.08 H17B 0.5116 0.2346 0.6187 0.08 C18 0.57805(12) 0.15162(14) 0.7483(2) 0.0581(5) H18A 0.5804 0.1909 0.8231 0.08 H18B 0.5707 0.0934 0.7804 0.08 C19 0.42806(11) 0.12442(11) 0.43852(18) 0.0460(4) C20 0.35149(12) 0.12890(11) 0.48298(19) 0.0499(4) H20 0.3489 0.1313 0.5736 0.08 C21 0.27903(12) 0.12987(12) 0.3938(2) 0.0539(5) C22 0.19946(14) 0.13183(16) 0.4478(3) 0.0684(6) F23 0.19854(9) 0.19130(12) 0.54236(17) 0.0973(5) F24 0.18397(11) 0.05872(12) 0.5046(3) 0.1286(8) F25 0.13575(9) 0.15083(16) 0.35812(18) 0.1216(7) C26 0.28037(14) 0.12594(15) 0.2590(2) 0.0663(6) H26 0.2316 0.1253 0.1997 0.08 C27 0.35586(16) 0.12292(16) 0.2143(2) 0.0702(6) H27 0.3578 0.1212 0.1235 0.08 C28 0.42895(14) 0.12245(14) 0.3015(2) 0.0591(5) H28 0.4791 0.1208 0.2686 0.08 O31 0.70266(9) 0.30926(9) 0.62125(18) 0.0738(5) C32 0.66099(13) 0.37670(12) 0.62665(19) 0.0527(5) O33 0.58513(11) 0.37610(11) 0.6255(2) 0.0935(6) C34 0.70438(14) 0.46195(12) 0.63243(18) 0.0562(5) C35 0.6612(2) 0.53938(14) 0.6406(2) 0.0754(7) O36 0.57910(18) 0.53960(15) 0.6404(3) 0.1133(8) H36 0.559 0.486 0.612 0.08 C37 0.7032(3) 0.61784(17) 0.6487(3) 0.1008(11) H37 0.6747 0.6694 0.6551 0.08 C38 0.7862(3) 0.6191(2) 0.6473(3) 0.1212(15) H38 0.8138 0.6719 0.6518 0.08 C39 0.8304(2) 0.5434(2) 0.6394(3) 0.1079(11) H39 0.8872 0.5451 0.6395 0.08 C40 0.78916(17) 0.46572(17) 0.6314(2) 0.0780(7) H40 0.8185 0.4146 0.6251 0.08 (hydrogen atoms were calculated according to well-established geometrical criteria) -
TABLE 2.12 Single crystal data and structure refinement of L-tartate form I Empirical formula 2 C20H22F3N4O+•C4H4O6 2−•2 H2O Fw 966.94 T [K] 293(2) λ[Å] 0.71073 Crystal system Triclinic Space group P 1 Unit cell dimensions a [Å] 9.4030(2) b [Å] 10.7370(3) c [Å] 11.7620(3) α [°] 98.355(1) β [°] 93.917(1) γ [°] 109.172(1) V [Å3] 1101.14(5) Z 1 Dm [g/cm3] 1.458 F(000) 506 Crystal size [mm3] 0.4 × 0.25 × 0.17 θ range [°] 2.5 → 27.5 Reflections collected 7358 Independent reflections 7358 [Rint = 0.0000] S 1.028 R [I > 2σ(I)] R1 = 0.0444, wR2 = 0.1196 R indices (all data) R1 = 0.0491, wR2 = 0.1257 -
TABLE 2.13 Single crystal data and structure refinement of fumarate form I Empirical formula 2 (C20H22F3N4O+)•C4H2O4 2−•C4H4O4 Fw 1012.96 T [K] 293(2) λ[Å] 0.71073 Crystal system Triclinic Space group P −1 Unit cell dimensions a [Å] 9.5900(2) b [Å] 11.6620(2) c [Å] 12.2070(3) α [°] 67.0130(11) β [°] 68.8250(10) γ [°] 88.8640(12) V [Å3] 1160.20(4) Z 1 Dm [g/cm3] 1.450 F(000) 528 Crystal size [mm3] 0.35 × 0.35 × 0.2 θ range [°] 3 → 26 Reflections collected 7642 Independent reflections 4536 [Rint = 0.0 199] S 1.058 R [I > 2σ(I)] R1 = 0.0452, wR2 = 0.0999 R indices (all data) R1 = 0.0594, wR2 = 0.1091 -
TABLE 2.14 Single crystal data and structure refinement of fumarate form II Empirical formula C20H22F3N4O+•0.5 C4H2O4 2−H2O•H2O Fw 466.46 T [K] 120(2) λ[Å] 0.71073 Crystal system Triclinic Space group P −1 Unit cell dimensions a [Å] 9.0720(3) b [Å] 10.7140(2) c [Å] 11.7530(8) α [°] 96.708(2) β [°] 95.355(2) γ [°] 109.214(2) V [Å3] 1060.71(11) Z 2 Dm [g/cm3] 1.460 F(000) 488 Crystal size [mm3] 0.20 × 0.15 × 0.1 θ range [°] 2.5 → 26 Reflections collected 6160 Independent reflections 4054 [Rint = 0.0662] S 1.061 R [I > 2σ(I)] R1 = 0.0618, wR2 = 0.1331 R indices (all data) R1 = 0.0825, wR2 = 0.1465 -
TABLE 2.15 Single crystal data and structure refinement of citrate form I Empirical formula C20H22F3N4O+•C6H9O8 −•C2H6O Fw 628.60 T [K] 293(2) λ[Å] 0.71073 Crystal system Orthorhombic Space group Pca21 Unit cell dimensions a [Å] 25.4880(4) b [Å] 15.6530(8) c [Å] 7.6090(16) α [°] 90 β [°] 90 γ [°] 90 V [Å3] 3035.7(7) Z 4 Dm [g/cm3] 1.375 F(000) 1320 Crystal size [mm3] 0.25 × 0.25 × 0.18 θ range [°] 2.5 → 25 Reflections collected 17271 Independent reflections 5321 [Rint = 0.0483] S 1.073 R [I > 2σ(I)] R1 = 0.0493, wR2 = 0.1044 R indices (all data) R1 = 0.0675, wR2 = 0.1126 -
TABLE 2.16 Single crystal data and structure refinement of mandelate form I Empirical formula C20H22F3N4O+•C8H7O3 − Fw 542.55 T [K] 293(2) λ[Å] 0.71073 Crystal system Orthorhombic Space group P 212121 Unit cell dimensions a [Å] 9.7220(2) b [Å] 22.5720(3) c [Å] 23.9740(4) α [°] 90 β [°] 90 γ [°] 90 V [Å3] 5261.0(2) Z 8 Dm [g/cm3] 1.370 F(000) 2272 Crystal size [mm3] 0.35 × 0.3 × 0.25 θ range [°] 1 → 26 Reflections collected 28800 Independent reflections 10298 [R(int) = 0.0760] S 1.040 R [I > 2σ(I)] R1 = 0.0732, wR2 = 0.1539 R indices (all data) R1 = 0.1163, wR2 = 0.1765 -
TABLE 2.17 Single crystal data and structure refinement of L-malate form I Empirical formula C24H22F3N4O+•C4H5O5 −•H2O Fw 542.51 T [K] 293(2) λ[Å] 0.71073 Crystal system Triclinic Space group P 1 Unit cell dimensions a [Å] 7.8000(2) b [Å] 8.0610(2) c [Å] 21.1650(3) α [°] 82.578(1) β [°] 82.526(1) γ [°] 77.692(1) V [Å3] 1282.05(3) Å3 Z 2 Dm [g/cm3] 1.405 F(000) 568 Crystal size [mm3] 0.25 × 0.25 × 0.2 θ range [°] 2 → 26 Reflections collected 8379 Independent reflections 8379 [Rint = 0.0000] S 1.026 R [I > 2σ(I)] R1 = 0.0350, wR2 = 0.0815 R indices (all data) R1 = 0.0384, wR2 = 0.0844 -
TABLE 2.18 a) Single crystal data and structure refinement of succinate form I Empirical formula 2 C20H22F3N4O+•C4H4O4 2−•2 H2O Fw 934.94 T [K] 293(2) λ[Å] 0.71073 Crystal system Triclinic Space group P −1 Unit cell dimensions a [Å] 9.5450(4) b [Å] 10.7120(5) c [Å] 11.7330(7) α [°] 97.597(2) β [°] 93.690(2) γ [°] 110.663(3) V [Å3] 1104.6(1) Z 1 Dm [g/cm3] 1.405 F(000) 490 Crystal size [mm3] 0.3 × 0.3 × 0.2 θ range [°] 3.5 → 26 Reflections collected 6382 Independent reflections 4176 [Rint = 0.0194] S 1.036 R [I > 2σ(I)] R1 = 0.0555, wR2 = 0.1386 R indices (all data) R1 = 0.0649, wR2 = 0.1484 -
TABLE 2.18 b) Atomic coordinates and temperature factor (Uiso) of succinate, form I atom x y z U (iso) O1 0.11215(14) −0.33344(13) 0.08086(12) 0.0588(4) C2 0.20693(19) −0.36147(17) 0.02653(15) 0.0473(4) N3 0.18520(18) −0.47601(15) −0.04935(14) 0.0510(4) H3 0.097 −0.541 −0.0650 0.07 C4 0.3180(2) −0.46756(17) −0.09559(14) 0.0471(4) C5 0.3527(2) −0.5538(2) −0.17731(17) 0.0582(5) H5 0.2808 −0.6367 −0.2123 0.07 C6 0.4993(3) −0.5117(2) −0.20481(18) 0.0655(5) H6 0.5258 −0.5667 −0.2606 0.07 C7 0.6070(3) −0.3898(2) −0.15142(19) 0.0659(5) H7 0.7047 −0.3653 −0.1712 0.07 C8 0.5727(2) −0.3037(2) −0.06925(17) 0.0575(5) H8 0.6455 −0.222 −0.0328 0.07 C9 0.42669(19) −0.34370(17) −0.04361(14) 0.0461(4) N10 0.35550(16) −0.28081(14) 0.03201(12) 0.0471(3) C11 0.4200(2) −0.14335(17) 0.09490(15) 0.0486(4) H11A 0.3413 −0.106 0.1011 0.07 H11B 0.495 −0.0883 0.052 0.07 C12 0.49289(19) −0.13732(16) 0.21523(14) 0.0438(4) H12A 0.4149 −0.1742 0.2638 0.07 H12B 0.5543 −0.1928 0.2106 0.07 N13 0.58818(14) 0.00287(13) 0.26891(11) 0.0378(3) H13 0.687(3) 0.048(3) 0.204(3) 0.109(9) C14 0.6605(2) 0.00347(17) 0.38462(14) 0.0457(4) H14A 0.7202 −0.0534 0.3767 0.07 H14B 0.5831 −0.0343 0.4333 0.07 C15 0.7605(2) 0.14425(18) 0.44207(15) 0.0489(4) H15A 0.7997 0.141 0.5196 0.07 H15B 0.8455 0.1773 0.3987 0.07 N16 0.68001(16) 0.23859(14) 0.44916(12) 0.0452(3) C17 0.6059(2) 0.23599(17) 0.33567(16) 0.0501(4) H17A 0.6818 0.2708 0.2849 0.07 H17B 0.5479 0.2942 0.3435 0.07 C18 0.50283(19) 0.09428(17) 0.28235(15) 0.0460(4) H18A 0.4242 0.0608 0.3312 0.07 H18B 0.4552 0.0956 0.2072 0.07 C19 0.75610(19) 0.36736(17) 0.51691(14) 0.0452(4) C20 0.7328(2) 0.48246(18) 0.49104(16) 0.0505(4) H20 0.6692 0.4758 0.4252 0.07 C21 0.8033(2) 0.60673(18) 0.56230(16) 0.0517(4) C22 0.7781(3) 0.7274(2) 0.5290(2) 0.0703(6) F23 0.8472(13) 0.7647(11) 0.4342(8) 0.100(3) F24 0.6390(9) 0.7062(9) 0.5010(11) 0.132(4) F25 0.8386(14) 0.8364(12) 0.6034(12) 0.126(4) F23 0.7798(13) 0.8151(14) 0.6255(14) 0.122(4) F24 0.6396(8) 0.6996(6) 0.4736(8) 0.087(2) F25 0.8708(10) 0.7912(12) 0.4664(10) 0.130(4) C26 0.8986(2) 0.6210(2) 0.66037(17) 0.0588(5) H26 0.9447 0.7044 0.7082 0.07 C27 0.9232(3) 0.5083(2) 0.68525(18) 0.0701(6) H27 0.9883 0.5162 0.7506 0.07 C28 0.8541(2) 0.3836(2) 0.61586(17) 0.0625(5) H28 0.8732 0.3092 0.6354 0.07 O31 0.78415(16) 0.08581(15) 0.12641(13) 0.0662(4) C32 0.8705(2) 0.0184(2) 0.11696(17) 0.0535(4) O33 0.8627(2) −0.0710(2) 0.17358(17) 0.0949(6) C34 0.9814(3) 0.0534(3) 0.0300(3) 0.0867(8) H34A 0.9416 0.0936 −0.0273 0.07 H34B 10.741 0.1224 0.0697 0.07 O35 1.1282(2) −0.1195(2) 0.26152(16) 0.0836(5) H35A 1.023(5) −0.114(4) 0.246(4) 0.165(16) H35B 1.107(4) −0.204(4) 0.196(3) 0.135(12) (hydrogen atoms were calculated according to well-established geometrical criteria) - A further object of the present invention is the use of the above salts and crystalline salt forms for the manufacture of a medicament for the treatment or prevention of the following diseases.
- The indication of the above salts and crystalline salt forms of the present invention may include all known indications for flibanserin, e.g. in the treatment of patients suffering from central nervous system disorders, in particular in affective disorders (e.g. depression like major depressive disorder, childhood depression, dysthymia, seasonal affective disorder, dysthymic disorder and minor depressive disorder; bipolar disorders), anxiety (incl. panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobia (simple phobia), social phobia (social anxiety disorder), obsessive-compulsive disorder (OCD), post-traumatic stress disorder, acute stress disorder, generalized anxiety disorder and anxiety disorder not otherwise specified), sleep and sexual disorders (e.g. Hypoactive Sexual Desire Disorder, premenstrual disorders like premenstrual dysphoria, premenstrual syndrome, premenstrual dysphoric disorder; sexual aversion disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorders like dyspareunia, vaginismus, noncoital sexual pain disorder; sexual dysfunction due to a general medical condition and substance-induced sexual dysfunction), psychosis, schizophrenia (including the disorganized type, the catatonic type, the paranoid type, the undifferentiated type, the residual type of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, and psychotic disorder not otherwise specified), personality disorders, mental organic disorders, mental disorders in childhood, aggressiveness, age associated memory impairment, for neuroprotection, the treatment and/or prevention of neurodegenerative diseases as well as cerebral ischaemia of various origins (e.g. epilepsy, hypoglycaemia, hypoxia, anoxia, brain trauma, brain oedema, amyotropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotension, cardiac infarct, brain pressure (elevated intracranial pressure), ischaemic and haemorrhagic stroke (stroke), global cerebral ischaemia during stoppage of the heart, diabetic polyneuropathy, tinnitus, perinatal asphyxia, cardiac hypertrophia (thickening of the heart muscle) and cardiac insufficiency (weakness of the heart muscle); anorexia nervosa (incl. binge-eating/purging type of anorexia nervosa and the restricting type of anorexia nervosa), Attention Deficit Hyperactivity Disorder (ADHD) (incl. ADHD predominantly combined type, ADHD predominantly inattentive type, and ADHD predominantly hyperactive-impulsive type), obesity (incl. exogenic obesity, hyperinsulinaemic obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity and central obesity), urinary incontinence (incl. overactive bladder syndrome, urgency, urge urinary incontinence, stress urinary incontinence, mixed urinary incontinence), chronic pain (incl. neuropathic pain, diabetic neuropathy, post-herpetic neuralgia (PHN), carpal tunnel syndrome (CTS), HIV neuropathy, phantom limb pain, complex regional pain syndrome (CPRS), trigeminal neuralgia/trigeminus neuralgia/tic douloureux, surgical intervention (e.g. post-operative analgesics), diabetic vasculopathy, capillary resistance or diabetic symptoms associated with insulitis, pain associated with angina, pain associated with menstruation, pain associated with cancer, dental pain, headache, migraine, trigeminal neuralgia, temporomandibular joint syndrome, myofascial pain muscular injury, fibromyalgia syndrome, bone and joint pain (osteoarthritis), rheumatoid arthritis, rheumatoid arthritis and edema resulting from trauma associated with burns, sprains or fracture bone pain due to osteoarthritis, osteoporosis, bone metastases or unknown reasons, gout, fibrositis, myofascial pain, thoracic outlet syndromes, upper back pain or lower back pain (wherein the back pain results from systematic, regional, or primary spine disease (radiculopathy), pelvic pain, cardiac chest pain, non-cardiac chest pain, spinal cord injury (SCI)-associated pain, central post-stroke pain, cancer neuropathy, AIDS pain, sickle cell pain and geriatric pain), Valvular Heart Disease (incl. valvular stenosis, valvular regurgitation, atresia of one of the valves, mitral valve prolapse), insomnia (including primary and secondary Insomnia), and vasomotor symptoms.
- Preferably, salts and crystalline salt forms can be used for the treatment of disorders of sexual desire, more preferably for HSDD (Hypoactive Sexual Desire Disorder).
- The present invention also relates to pharmaceutical compositions comprising the above-mentioned salts or crystalline salt forms of the present invention.
- The above salts and crystalline salt forms of the present invention, may be incorporated into the conventional pharmaceutical preparation in solid, liquid or spray form. The composition may, for example, be presented in a form suitable for oral, rectal, parenteral administration or for nasal inhalation: preferred forms includes for example, capsules, tablets, coated tablets, ampoules, suppositories and nasal spray.
- The active ingredient may be incorporated in excipients or carriers con-ventionally used in pharmaceutical compositions such as, for example, talc, arabic gum, lactose, gelatine, magnesium stearate, corn starch, acqueous or non acqueous vehicles, polyvynil pyrrolidone, semisynthetic glicerides of fatty acids, benzalconium chloride, sodium phosphate, EDTA, polysorbate 80. The compositions are advantageously formulated in dosage units, each dosage unit being adapted to supply a single dose of the active ingredient. The dosis range applicable per day is between 0.1 to 400, preferably between 1.0 to 300, more preferably between 2 to 200 mg.
- Each dosage unit may conveniently contain from 0.01 mg to 100 mg, preferably from 0.1 to 50 mg.
- Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
- Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
- Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. of a flavouring such as vanilline or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
- Solutions for injection are prepared in the usual way, e.g. of with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, and transferred into injection vials or ampoules.
- Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
- Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
-
FIG. 1.1 a: X-ray powder diffraction diagram of HCl 1=chloride, form I; -
FIG. 1.1 b: X-ray powder diffraction diagram of HCl 3=chloride, form III; -
FIG. 1.2 a: X-ray powder diffraction diagram of HBr 1=hydrobromid, form I; -
FIG. 1.2 b: X-ray powder diffraction diagram of HBr 3=hydrobromid, form III; -
FIG. 1.3 : X-ray powder diffraction diagram of Eds 1=edisylate, form I; -
FIG. 1.4 : X-ray powder diffraction diagram of Tos 1=tosylate, form I; -
FIG. 1.5 : X-ray powder diffraction diagram of Mes 1=mesylate, form I; -
FIG. 1.6 : X-ray powder diffraction diagram of Bes 1=besylate, form I; -
FIG. 1.7 a: X-ray powder diffraction diagram of Oxa 1=oxalate, form I; -
FIG. 1.7 b: X-ray powder diffraction diagram ofOxa 5=oxalate, form V; -
FIG. 1.8 : X-ray powder diffraction diagram of Sac 1=saccharinate, form I; -
FIG. 1.9 : X-ray powder diffraction diagram of Pho 1=phosphate, form I; -
FIG. 1.10 a: X-ray powder diffraction diagram of Mae 1=maleate, form I; -
FIG. 1.10 b: X-ray powder diffraction diagram of Mae 3=maleate, form III; -
FIG. 1.11 : X-ray powder diffraction diagram of Ets 1=ethanesulfonate, form I; -
FIG. 1.12 X-ray powder diffraction diagram of Cas 1=camphorsulfonate, form I; -
FIG. 1.13 : X-ray powder diffraction diagram of Mao 1=malonate, form I; -
FIG. 1.14 : X-ray powder diffraction diagram of L-Tar 1=L-tartrate, form I; -
FIG. 1.15 a: X-ray powder diffraction diagram of Fum 1=fumarate, form I; -
FIG. 1.15 b: X-ray powder diffraction diagram of Fum 2=fumarate, form II; -
FIG. 1.16 X-ray powder diffraction diagram of Gly 1=glycolate, form I; -
FIG. 1.17 : X-ray powder diffraction diagram of Cit 1=citrate, form I; -
FIG. 1.18 : X-ray powder diffraction diagram of Man 1=mandelate, form I; -
FIG. 1.19 : X-ray powder diffraction diagram of L-Mal 1=L-malate, form I; -
FIG. 1.20 X-ray powder diffraction diagram of Nas 1=naphtalene-sulfonate, form I; -
FIG. 1.21 X-ray powder diffraction diagram of TOS 2=tosylate, form II; -
FIG. 1.22 X-ray powder diffraction diagram of Fum 3=fumarate, form III; -
FIG. 1.23 X-ray powder diffraction diagram of Cas 2=camphorsulfonate, form II; -
FIG. 1.24 X-ray powder diffraction diagram of Gly 3=glycolate, form II. - The harvested crystals may be characterized by X-ray powder diffraction and thermal analysis (DSC). If suitable single crystals grow, single crystal X-ray structure analysis may be performed. The following equipment was used to characterize the crystalline salts forms.
- X-Ray Powder Diffraction (=XRPD)
- XRPD patterns were obtained using a high throughput XRPD set-up. The plates were mounted on a Bruker GADDS diffractometer equipped with a Hi-Star area detector. The diffractometer was calibrated using Silver Behenate for the long d-spacings and corundum for the short d-spacings.
- The data collection was carried out at room temperature using monochromatic CuKα radiation in the region of 2Θ between 1.5 and 41.5°. The diffraction pattern of each well was collected with an exposure time of 3-4 minutes.
- Single Crystal X-Ray Structure Analysis
- Suitable single crystals were selected and glued to a glass fibre, which is mounted on a X-ray diffraction goniometer. X-ray diffraction data were collected for the mounted crystals at a temperature of 233K using a KappaCCD system and MoKα radiation generated by a FR590 X-ray generator (Bruker Nonius Delft, The Netherlands).
- Unit-cell parameters and crystal structure were determined and refined using the software package maXus (Mackay et al., 1997).
- Thermal Analysis (DSC)
- Melting properties were obtained from differential scanning calorimetry (=DSC) thermograms recorded on a DSC822e (Mettler-Toledo GmbH, Switzerland). The DSC822e was calibrated for temperature and enthalpy with a small piece of indium (Tfus=156.6° C., ΔHfus=28.45 J/g). Samples were sealed in standard 40 μl aluminium pans and heated in the DSC from 25 to 300° C. with a heating rate of 20° C./min. Dry nitrogen gas was used to purge the DSC equipment during measurements at a flow rate of 50 ml/min. The melting temperature used was the Tfus (onset) temperature of the corresponding melting peak in the DSC diagram. The accuracy of the melting points specified is about ±5° C.
- Hygroscopicity
- IGAsorp water sorption monitor from Hiden Isochema was used for the analysis of the hygroscopical behaviour at room temperature.
- humidity profile: from 10-90% r.h. in steps of 10%, sorption as well as desorption profiles were registered
weight-in quantity: 10-20 mg - Solubility
- Solubility of the different crystalline salt forms in water was determined by adding approx. 5 mg of compound into 5 ml of water at room temperature. The mixture was vigorously shaken for 2 hours at room temperature. Afterwards the undissolved solid was removed by filtering through a 0.45 μm PTFE filter, in the filtrate the dissolved amount of compound was determined by UV-spectroscopy.
- The process is illustrated by the following example of manufacturing process of the salts and crystalline salt forms, as can be done in parallel in 96 well assay plates (maximum volume of each well is about 200 μl).
- Approximately 1 g of the free base of flibanserin were dissolved in 10 ml TFE/water 80:20. The acids used to prepare the salts were dissolved in different solvents such that the molar ratio of the flibanserin to the respective acid was set according to the information given in Table 3 under “ratio base/acid”. Fumaric acid was dissolved in THF/water 80:20, HCl in water and all other acids used were dissolved in TFE/water 80:20. However it is to mention that all other solvents which are able to dissolve the acid used could have been used. The 96 well plates were then placed in a vacuum chamber (1 kPa) at room temperature for 24 h in order to evaporate the solvent. Afterwards, different solvents were added in each well according to the information given in Table 3 under “crystallization solvent”, and the well plates were sealed and heated up to 50° C. at a heating rate of approx. 5° C./min. The plate stayed then for an additional 30 minutes at 50° C. Afterwards, the plate was cooled at a cooling rate of 5° C./h to a final temperature of 3 or 20° C. according to the information given in Table 3 under “Tfinal[° C.]”. At this temperature, the plates remained for a holding time of 24 h. The plates were then opened and the solids were collected by filtration. All salts specified in table 3 were synthesized according to the above specification.
-
TABLE 3 Conditions for the preparation of the different salts of 1-[2-(4-(3-trifluoro- methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one salt salt form ratio crystallization Tfinal form full name used acid base/a solvent [° C.] HCl chloride, form I hydrochloric acid 1:1 ethanol/water (80:20) 3 HCl3 chloride, form III hydrochloric acid 1:1 water/NMP* (80:20) 20 HBr 1 bromide from I hydrobromic acid 1:1 dichlormethane 20 HBr 3 bromide from III hydrobromic acid 1:1 methanol 20 Eds1 edisylate form I ethane-1,2 1:1 methanol 20 disulfonic acid Tos 1 tosylate form I p-toluenesulfonic 1:1 THF* 20 acid Mes 1 mesylate form I methanesulfonic 1:1 TBME* 20 acid Bes 1 besylate form I benzenesulfonic 1:1 TBME* 20 acid Oxa 1 oxalate form I oxalic acid 1:1 1,2 Dimethoxyethane 20 Oxa 5 oxalate form V oxalic acid 1:1 water/acetone (20:80) 3 Sac1 sacharinate form I sacharine 1:1 dichloromethane 3 Pho phosphate form I phsophoric acid 1:1 cyclohexanone 20 Mae1 maleate form I maleaic acid 1:1 THF* 3 Mae3 maleate form III maleaic acid 1:1 propyl acetate 20 Ets ethanesulfonate ethanesulfonic 1:1 1,2 Dimethoxyethane 20 acid Cas1 camphorsulfonate campher-10 1:1 cyclohexane 20 form I sulfonic acid Mao 1 malonate form I malonic acid 1:1 acetone/water (80:20) 3 Mao 2 malonate form II malonic acid 1:1 tert-Butanol 3 Mao 6 malonic form VI malonic acid 1:1 Nitromethane 3 Sal 1 salicylate form I salicylic acid 1:1 DMSO*/water (20:80) 3 L-Tart 1 L-tartate form L-tartaric acid 1:1 ethanol 20 Fum 1 fumerate form I fumaric acid 2:1 chloroform 20 Fum 2 fumerate form II fumaric acid 2:1 nitromethane 20 Gly 1 glycolate form I glycolic acid 1:1 TBME* 20 Cit1 citrate form I citric acid 2:1 ethanol/water (80:20) 20 Man 1 mandelate form I L-mandelic acid 1:1 ethanol 20 L-Mal 1 L-malate form I L-malic acid 1:1 ethanol 3 Suc 1 succinate form I succinic acid 1:1 H2O 20 Nas1 naphtalene- naphtalene-2- 1:1 2-butanone 3 sulfonate form I sulfonic acid Tos 2 tosylate form II p-toluenesulfonic 1:1 ethanol 20 (=anhydrous form) acid Fum 3 fumarate, form III fumaric acid 1:1 chloroform 20 (=anhydrous form) Cas 2 camphorsulfonate form II campher-10 1:1 ethanol 20 (= anhydrous form) sulfonic acid Gly 2 glycolate form II glycolic acid 1:1 TBME* 20 (=hydrate form) *THF = tetrahydrofurane *DMSO = dimethylsulfoxide *NMP = 1-methyl-2-pyrrolidinone *TBME = tert-butyl methyl ether *TFE = 2,2,2,-Trifuoroethanol - The Examples which follow illustrate the present invention without restricting its scope:
-
-
A) Tablets per tablet active substance 100 mg lactose 240 mg corn starch 340 mg polyvinylpyrrolidone 45 mg magnesium stearate 15 mg 740 mg - The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.
-
B) Tablets per tablet active substance 80 mg corn starch 190 mg lactose 55 mg microcrystalline cellulose 35 mg polyvinylpyrrolidone 15 mg sodium-carboxymethyl starch 23 mg magnesium stearate 2 mg 400 mg - The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
-
C) Coated tablets per coated tablet active substance 5 mg corn starch 41.5 mg lactose 30 mg polyvinylpyrrolidone 3 mg magnesium stearate 0.5 mg 80 mg - The active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water. The moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45° C. and the granules are then passed through the same screen. After the magnesium stearate has been mixed in, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine. The tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc. The finished coated tablets are polished with wax.
-
D) Capsules per capsule active substance 1 50 mg Corn starch 268.5 mg Magnesium stearate 1.5 mg 420 mg - The substance and corn starch are mixed and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The finished mixture is packed into size 1 hard gelatine capsules.
-
E) Ampoule solution active substance 50 mg sodium chloride 50 mg water for inj. 5 ml - The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.
-
F) Suppositories active substance 50 mg solid fat 1650 mg 1700 mg - The hard fat is melted. At 40° C. the ground active substance is homogeneously dispersed. It is cooled to 38° C. and poured into slightly chilled suppository moulds.
Claims (7)
1. A salt of the compound 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one selected from the group consisting of:
I. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one chloride having a melting point of Tfus (onset)=215±5° C.;
II. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one chloride having a melting point of Tfus (onset)=217±5° C.;
III. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one bromide having a melting point of Tfus (onset)=252±5° C. and peaks in the X-ray powder diffractogram which occur at d=3.48±0.05 Å, d=3.33±0.05 Å, d=4.28±0.05 Å, d=3.43±0.05 Å, and d=16.03±0.05 Å;
IV. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one bromide having a melting point of Tfus (onset)=252±5° C. and peaks in the X-ray powder diffractogram which occur at d=15.52±0.05 Å, d=5.15±0.05 Å, d=4.60±0.05 Å, d=4.36±0.05 Å, and d=3.94±0.05 Å;
V. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one edisylate having a melting point of Tfus (onset)=144±5° C.;
VI. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one tosylate having a melting point of Tfus (onset)=238±5° C.;
VII. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one mesylate having a melting point of Tfus (onset)=207±5° C.;
VIII. a crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one besylate having a melting point of Tfus (onset)=247±5° C.;
IX. a crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one oxalate having a melting point of Tfus (onset)=209±5° C.;
X. a crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one oxalate having a melting point of Tfus (onset)=254±5° C.;
XI. a crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one sacharinate having a melting point of Tfus (onset)=90±5° C.;
XII. a crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one phosphate having a melting point of Tfus (onset)=182±5° C.;
XIII. a crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one maleate having a melting point of Tfus (onset)=98±5° C.;
XIV. a crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one maleate having a melting point of Tfus (onset)=172±5° C.;
XV. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one ethansulfonate having a melting point of Tfus (onset)=207±5° C.;
XVI. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one camphorsulfonate having a melting point of Tfus (onset)=217±5° C.;
XVII. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one malonate having a melting point of Tfus (onset)=103±5° C.;
XVIII. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one malonate having the following characteristics:
XIX. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one malonate having the following characteristics:
XX.
XXI. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one salicylate having the following characteristics:
XXII. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one L-tartrate having a melting point of Tfus (onset)=151±5° C.;
XXIII. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one hemifumarate having a melting point of Tfus (onset)=195±5° C.;
XXIV. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one fumarate having a melting point of Tfus (onset)=193±5° C.;
XXV. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one glycolate (form I) (hydrate form) having a melting point of Tfus (onset)=139±5° C.;
XXVI. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one citrate, characterized by having a melting point of Tfus (onset)=176±5° C.;
XXVII. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one mandelate having a melting point of Tfus (onset)=148±5° C.;
XXVIII. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one L-malate having a melting point of Tfus (onset)=176±5° C.;
XXIX. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one succinate having the following characteristics:
XXX. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one naphthalenesulfonate having peaks in the X-ray powder diffractogram which occur at d=4.92±0.05 Å, d=3.43±0.05 Å, d=4.00±0.05 Å, and d=3.96±0.05 Å;
XXXI. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one tosylate (form II) (anhydrous form) having a melting point of Tfus (onset)=241±5° C.;
XXXII. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one fumarate (form III) (anhydrous form) having a melting point of Tfus (onset)=202±5° C.;
XXXIII. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one camphorsulfonate (form II) (anhydrous form) having a melting point of Tfus (onset)=231±5° C.; and
XXXIV. crystalline 1-[2-(4-(3-trifluoro-methyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one glycolate (form II) (hydrate form) having a melting point of Tfus (onset)=231±5° C.
2. (canceled)
3. A pharmaceutical composition comprising the crystalline salt forms according to claim 1 and a pharmaceutically acceptable excipients.
4. A process for preparing a crystalline salt according to claim 1 , comprising:
i) dissolving the free base of flibanserin and the acid providing the anion for salt formation in a suitable solvent;
ii) mixing the free base of flibanserin with the acid at a predetermined base/acid molar ratio, which is selected from 1:1 or 2:1 depending on the acid;
iii) removing the solvent;
iv) adding a suitable crystallization solvent to the residue obtained by step iii), and heating the reaction mixture slowly up to about 50° C.; and leaving it to stand for a further period of time;
v) slowly cooling down the reaction mixture to a suitable crystallization temperature and leaving it to stand until enough crystals are formed; and
vi) isolating the precipitated crystals.
5. A method a treating a disorder in a patient in need thereof, the method comprising administering an effective amount of a compound according to claim 1 to the patient.
6. The method according to claim 5 , wherein the disorder is Hypoactive Sexual Desire Disorder.
7. The method according to claim 5 , wherein the disorder is selected from a central nervous system disorder, including an affective disorder (e.g., depression like major depressive disorder, childhood depression, dysthymia, seasonal affective disorder, dysthymic disorder and minor depressive disorder; bipolar disorders), anxiety (e.g., panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobia (simple phobia), social phobia (social anxiety disorder), obsessive-compulsive disorder (OCD), post-traumatic stress disorder, acute stress disorder, generalized anxiety disorder and anxiety disorder not otherwise specified), sleep and sexual disorders (e.g., Hypoactive Sexual Desire Disorder, premenstrual disorders like premenstrual dysphoria, premenstrual syndrome, premenstrual dysphoric disorder; sexual aversion disorder, sexual arousal disorder, orgasmic disorder, sexual pain disorders like dyspareunia, vaginismus, noncoital sexual pain disorder; sexual dysfunction due to a general medical condition and substance-induced sexual dysfunction), psychosis, schizophrenia (including the disorganized type, the catatonic type, the paranoid type, the undifferentiated type, the residual type of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, and psychotic disorder not otherwise specified), personality disorders, mental organic disorders, mental disorders in childhood, aggressiveness, age associated memory impairment, for neuroprotection, the treatment and/or prevention of neurodegenerative diseases as well as cerebral ischaemia of various origins (e.g. epilepsy, hypoglycaemia, hypoxia, anoxia, brain trauma, brain oedema, amyotropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotension, cardiac infarct, brain pressure (elevated intracranial pressure), ischaemic and haemorrhagic stroke (stroke), global cerebral ischaemia during stoppage of the heart, diabetic polyneuropathy, tinnitus, perinatal asphyxia, cardiac hypertrophia (thickening of the heart muscle) and cardiac insufficiency (weakness of the heart muscle); anorexia nervosa (incl. binge-eating/purging type of anorexia nervosa and the restricting type of anorexia nervosa), Attention Deficit Hyperactivity Disorder (ADHD) (incl. ADHD predominantly combined type, ADHD predominantly inattentive type, and ADHD predominantly hyperactive-impulsive type), obesity (incl. exogenic obesity, hyperinsulinaemic obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity and central obesity), urinary incontinence (incl. overactive bladder syndrome, urgency, urge urinary incontinence, stress urinary incontinence, mixed urinary incontinence), chronic pain (incl. neuropathic pain, diabetic neuropathy, post-herpetic neuralgia (PHN), carpal tunnel syndrome (CTS), HIV neuropathy, phantom limb pain, complex regional pain syndrome (CPRS), trigeminal neuralgia/trigeminus neuralgia/tic douloureux, surgical intervention (e.g. post-operative analgesics), diabetic vasculopathy, capillary resistance or diabetic symptoms associated with insulitis, pain associated with angina, pain associated with menstruation, pain associated with cancer, dental pain, headache, migraine, trigeminal neuralgia, temporomandibular joint syndrome, myofascial pain muscular injury, fibromyalgia syndrome, bone and joint pain (osteoarthritis), rheumatoid arthritis, rheumatoid arthritis and edema resulting from trauma associated with burns, sprains or fracture bone pain due to osteoarthritis, osteoporosis, bone metastases or unknown reasons, gout, fibrositis, myofascial pain, thoracic outlet syndromes, upper back pain or lower back pain (wherein the back pain results from systematic, regional, or primary spine disease (radiculopathy), pelvic pain, cardiac chest pain, non-cardiac chest pain, spinal cord injury (SCI)-associated pain, central post-stroke pain, cancer neuropathy, AIDS pain, sickle cell pain and geriatric pain), Valvular Heart Disease (incl. valvular stenosis, valvular regurgitation, atresia of one of the valves, mitral valve prolapse), insomnia (including primary and secondary Insomnia), and vasomotor symptoms.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08171699.5 | 2008-12-15 | ||
EP08171699 | 2008-12-15 | ||
PCT/EP2009/067007 WO2010079045A2 (en) | 2008-12-15 | 2009-12-14 | New salts |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/067007 A-371-Of-International WO2010079045A2 (en) | 2008-12-15 | 2009-12-14 | New salts |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/484,900 Continuation US9546141B2 (en) | 2008-12-15 | 2014-09-12 | Salts |
Publications (2)
Publication Number | Publication Date |
---|---|
US20120122883A1 true US20120122883A1 (en) | 2012-05-17 |
US20120322810A9 US20120322810A9 (en) | 2012-12-20 |
Family
ID=42115616
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/131,926 Abandoned US20120322810A9 (en) | 2008-12-15 | 2009-12-14 | New salts |
US14/484,900 Expired - Fee Related US9546141B2 (en) | 2008-12-15 | 2014-09-12 | Salts |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/484,900 Expired - Fee Related US9546141B2 (en) | 2008-12-15 | 2014-09-12 | Salts |
Country Status (5)
Country | Link |
---|---|
US (2) | US20120322810A9 (en) |
EP (1) | EP2376457A2 (en) |
JP (1) | JP2012512145A (en) |
CA (1) | CA2686480A1 (en) |
WO (1) | WO2010079045A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110015207A1 (en) * | 2006-12-20 | 2011-01-20 | Boehringer Ingelheim International Gmbh | Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
US8785458B2 (en) | 2005-08-03 | 2014-07-22 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US9782403B2 (en) | 2001-10-20 | 2017-10-10 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
CN113683570A (en) * | 2016-01-31 | 2021-11-23 | 孟晓明 | New crystal form of flibanserin, preparation method and application thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017076356A1 (en) * | 2015-11-05 | 2017-05-11 | 苏州晶云药物科技有限公司 | Novel crystal form of flibaserin, and preparation method therefor |
WO2017142002A1 (en) * | 2016-02-17 | 2017-08-24 | 大正製薬株式会社 | Crystal forms of free c-4"-substituted macrolide compound and salt thereof, and production methods therefor |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3362956A (en) | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
FI791926A (en) | 1978-06-20 | 1979-12-21 | Synthelabo | PHENYLPIPERAZINE DERIVATIVES |
DE3126703A1 (en) | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | BROMHEXIN RETARD FORM AND METHOD FOR THEIR PRODUCTION |
JPS58134033A (en) | 1982-02-02 | 1983-08-10 | Fujisawa Pharmaceut Co Ltd | Drug composition |
IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
NL8601494A (en) | 1985-06-22 | 1987-01-16 | Sandoz Ag | THIAZOLS, THEIR PREPARATIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. |
US4954503A (en) | 1989-09-11 | 1990-09-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(1-substituted-4-piperazinyl)-1H-indazoles |
HUT68769A (en) | 1991-05-07 | 1995-07-28 | Merck & Co Inc | FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE |
IT1251144B (en) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | BENZIMIDAZOLONE DERIVATIVES |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
DE4216364A1 (en) | 1991-12-14 | 1993-11-25 | Thomae Gmbh Dr K | Pyridyl derivs. with antithrombotic properties |
JP3204510B2 (en) | 1993-04-05 | 2001-09-04 | コンペティティブ テクノロジーズ,インク. | Diagnosis and treatment of erectile dysfunction |
US5883094A (en) | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
DE69729950T2 (en) | 1996-11-06 | 2005-07-28 | Wockhardt Europe Ltd. | Released-release drug delivery system for acid labile drugs |
CA2334551A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
WO2000064441A2 (en) | 1999-04-28 | 2000-11-02 | Respiratorius Ab | Compound for use as a medicament for treatment of disorders involving bronchocontraction |
US20030055070A1 (en) | 1999-07-01 | 2003-03-20 | Wilma Harrison | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction |
IT1313625B1 (en) | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | BENZIMIDAZOLONIC DERIVATIVES WITH MIXED AFFINITY FOR DYEROTONIN AND DOPAMIN RECEPTORS. |
US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
US20020052370A1 (en) | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
GB0105893D0 (en) | 2001-03-09 | 2001-04-25 | Pfizer Ltd | Pharmaceutically active compounds |
GB0106446D0 (en) | 2001-03-15 | 2001-05-02 | Vernalis Res Ltd | Chemical compounds |
EP1256343B1 (en) * | 2001-05-11 | 2006-07-05 | Jürgen K. Dr. Beck | Flibanserin for the treatment of extrapyramidal movement disorders |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
UA76767C2 (en) * | 2001-08-02 | 2006-09-15 | Бідакем С.П.А. | Stable polymorph modification of flibanserin, method for industrial production thereof and use thereof for preparing medicaments |
DE10138273A1 (en) | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Medicines with neuroprotective effects |
HUP0202719A3 (en) | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
DE10149674A1 (en) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US20040048877A1 (en) | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
EP1551393A4 (en) | 2002-07-30 | 2010-06-16 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
US20050037983A1 (en) | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
MXPA06002731A (en) | 2003-09-11 | 2006-06-05 | Xenoport Inc | Treating and/or preventing urinary incontinence using prodrugs of gaba analogs. |
AU2005235422B2 (en) | 2004-04-22 | 2011-08-11 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders II |
US20060014757A1 (en) | 2004-07-14 | 2006-01-19 | Boehringer Ingelheim Pharmaceuticals | Method for the treatment of anorexia nervosa |
WO2006024471A1 (en) | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
JP2008540356A (en) | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Drug abuse treatment methods |
US20060258640A1 (en) | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
CA2578626C (en) | 2005-06-27 | 2011-07-19 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
EP1912650B8 (en) | 2005-08-03 | 2017-10-18 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
EP2037927B1 (en) | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
EP2043648A1 (en) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Use of flibanserin for the treatment of sexual disorders in females |
CL2007002214A1 (en) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP |
AU2007286288A1 (en) * | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
EA200900270A1 (en) | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | SYSTEMS OF ADJUSTABLE GRINDING AND METHOD OF THEIR PREPARATION |
ATE524446T1 (en) | 2006-12-20 | 2011-09-15 | Boehringer Ingelheim Int | SULFATED BENZIMIDAZOLONE DERIVATIVES WITH MIXED SEROTONIN RECEPTOR AFFINITY |
US20100093754A1 (en) | 2007-03-28 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders |
-
2009
- 2009-11-26 CA CA 2686480 patent/CA2686480A1/en not_active Abandoned
- 2009-12-14 US US13/131,926 patent/US20120322810A9/en not_active Abandoned
- 2009-12-14 WO PCT/EP2009/067007 patent/WO2010079045A2/en active Application Filing
- 2009-12-14 EP EP09774901A patent/EP2376457A2/en not_active Withdrawn
- 2009-12-14 JP JP2011540128A patent/JP2012512145A/en active Pending
-
2014
- 2014-09-12 US US14/484,900 patent/US9546141B2/en not_active Expired - Fee Related
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9782403B2 (en) | 2001-10-20 | 2017-10-10 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US11058683B2 (en) | 2001-10-20 | 2021-07-13 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US8785458B2 (en) | 2005-08-03 | 2014-07-22 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US9730927B2 (en) | 2005-08-03 | 2017-08-15 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US10335407B2 (en) | 2005-08-03 | 2019-07-02 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US10874668B2 (en) | 2005-08-03 | 2020-12-29 | Sprout Pharmaceuticals, Inc. | Use of Flibanserin in the treatment of obesity |
US20110015207A1 (en) * | 2006-12-20 | 2011-01-20 | Boehringer Ingelheim International Gmbh | Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
US8722682B2 (en) | 2006-12-20 | 2014-05-13 | Sprout Pharmaceuticals, Inc. | Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity |
CN113683570A (en) * | 2016-01-31 | 2021-11-23 | 孟晓明 | New crystal form of flibanserin, preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2686480A1 (en) | 2010-06-15 |
WO2010079045A2 (en) | 2010-07-15 |
US20120322810A9 (en) | 2012-12-20 |
US20150126524A1 (en) | 2015-05-07 |
JP2012512145A (en) | 2012-05-31 |
WO2010079045A3 (en) | 2010-12-23 |
US9546141B2 (en) | 2017-01-17 |
EP2376457A2 (en) | 2011-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9546141B2 (en) | Salts | |
US11472773B2 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
WO2014138368A1 (en) | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor | |
CN105008333B (en) | The sulfate of the amine of N (3 (base of 4 (3 (diisobutylamino) propyl group) piperazine 1) propyl group) 1H benzos [d] imidazoles 2, its preparation and application thereof | |
EP2455368A1 (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof | |
US20110098321A1 (en) | Salts of methyl 2-((r)-(3-chlorophenyl)((r)-1-((s)-2-(methylamino)-3-((r)-tetrahydro-2h-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate | |
WO2021121146A1 (en) | Crystal form a of aminopyrimidine mesylate compound, preparation method therefor, and application thereof | |
JP5486008B2 (en) | 1-Butyl-2-hydroxyaralkylpiperazine derivatives and their use as antidepressants | |
EA029678B1 (en) | Piperidinium quaternary salts | |
JP6491653B2 (en) | Nalmefene salt as a drug to reduce alcohol consumption or prevent excessive alcohol consumption | |
CN106800550B (en) | 5-hydroxytryptamine receptor agonist | |
CN103003253A (en) | Acid addition salts of the 2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3- (4-methylpiperazin-1-yl)cyclohexyl] acetamide and the use thereof as bradykinin b1 receptor antagonists | |
US20110251214A1 (en) | Monohydrate of pardoprunox |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAZUREK, JAROSLAW;POP, MIHAELA;SIGNING DATES FROM 20110908 TO 20111005;REEL/FRAME:027138/0220 |
|
AS | Assignment |
Owner name: SPROUT PHARMACEUTICALS, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOEHRINGER INGELHEIM INTERNATIONAL GMBH;REEL/FRAME:027705/0660 Effective date: 20111209 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |